

CVS CAREMARK CORP  
Form 10-Q  
July 31, 2008  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

**Quarterly Report Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**For the Quarterly Period Ended June 28, 2008**

**Commission File Number 001-01011**

**CVS CAREMARK CORPORATION**

*(Exact name of registrant as specified in its charter)*

**Delaware**  
*(State of Incorporation)*

**05-0494040**  
*(I.R.S. Employer Identification Number)*  
**One CVS Drive, Woonsocket, Rhode Island 02895**

Edgar Filing: CVS CAREMARK CORP - Form 10-Q

*(Address of principal executive offices)*

**Telephone: (401) 765-1500**

*(Former name, former address and former fiscal year, if changed since last report)*

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check One):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Common Stock, \$0.01 par value, issued and outstanding at July 28, 2008:

1,435,184,000 shares

**Table of Contents**

**INDEX**

	<b>Page</b>
<b>Part I</b>	
Item 1. Financial Statements	
<u>Consolidated Condensed Statements of Operations (Unaudited) -     Thirteen and Twenty-Six Weeks Ended June 28, 2008 and June 30, 2007</u>	2
<u>Consolidated Condensed Balance Sheets (Unaudited) -     As of June 28, 2008 and December 29, 2007</u>	3
<u>Consolidated Condensed Statements of Cash Flows (Unaudited) -     Twenty-Six Weeks Ended June 28, 2008 and June 30, 2007</u>	4
<u>Notes to Consolidated Condensed Financial Statements (Unaudited)</u>	5
<u>Report of Independent Registered Public Accounting Firm</u>	17
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	18
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	37
Item 4. <u>Controls and Procedures</u>	37
<b>Part II</b>	
Item 1. <u>Legal Proceedings</u>	38
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	39
Item 4. <u>Submission of Matters to a Vote of Security Holders</u>	40
Item 5. <u>Other Information</u>	41
Item 6. <u>Exhibits</u>	42
<u>Signature Page</u>	42

**Table of Contents**

Part I

Item 1

## CVS Caremark Corporation

## Consolidated Condensed Statements of Operations

(Unaudited)

	13 Weeks Ended		26 Weeks Ended	
	June 28, 2008	June 30, 2007	June 28, 2008	June 30, 2007
<i>(In millions, except per share amounts)</i>				
Net revenues	\$ 21,140.3	\$ 20,703.3	\$ 42,466.3	\$ 33,891.9
Cost of revenues	16,767.1	16,544.8	33,800.1	26,430.2
Gross profit	4,373.2	4,158.5	8,666.2	7,461.7
Operating expenses	2,895.1	2,848.7	5,818.0	5,415.4
Operating profit	1,478.1	1,309.8	2,848.2	2,046.3
Interest expense, net	114.7	105.9	245.6	169.8
Earnings from continuing operations before income tax provision	1,363.4	1,203.9	2,602.6	1,876.5
Income tax provision	539.9	480.3	1,030.6	744.0
Earnings from continuing operations	823.5	723.6	1,572.0	1,132.5
Loss from discontinued operations, net of tax benefit of \$30.1 million	(48.7)		(48.7)	
Net earnings	774.8	723.6	1,523.3	1,132.5
Preference dividends, net of income tax benefit	3.6	3.5	7.1	7.0
Net earnings available to common shareholders	\$ 771.2	\$ 720.1	\$ 1,516.2	\$ 1,125.5
<b>Basic earnings per common share:</b>				
Earnings from continuing operations	\$ 0.57	\$ 0.48	\$ 1.09	\$ 0.94
Loss from discontinued operations	(0.03)		(0.03)	
Net earnings	\$ 0.54	\$ 0.48	\$ 1.06	\$ 0.94
Weighted average basic common shares outstanding	1,431.8	1,492.4	1,430.8	1,199.2
<b>Diluted earnings per common share:</b>				
Earnings from continuing operations	\$ 0.56	\$ 0.47	\$ 1.07	\$ 0.91
Loss from discontinued operations	(0.03)		(0.03)	
Net earnings	\$ 0.53	\$ 0.47	\$ 1.04	\$ 0.91
Weighted average diluted common shares outstanding	1,468.7	1,542.5	1,468.5	1,241.4
<b>Dividends declared per common share</b>	\$ 0.06000	\$ 0.06000	\$ 0.12000	\$ 0.10875

See accompanying notes to consolidated condensed financial statements (unaudited).



**Table of Contents****Part I****Item 1**

**CVS Caremark Corporation**  
**Consolidated Condensed Balance Sheets**  
**(Unaudited)**

<i>(In millions, except share and per share amounts)</i>	June 28, 2008	December 29, 2007
<b>Assets:</b>		
Cash and cash equivalents	\$ 615.7	\$ 1,056.6
Short-term investments		27.5
Accounts receivable, net	4,457.7	4,579.6
Inventories	8,001.4	8,008.2
Deferred income taxes	360.4	329.4
Other current assets	170.2	148.1
<b>Total current assets</b>	<b>13,605.4</b>	<b>14,149.4</b>
Property and equipment, net	6,305.1	5,852.8
Goodwill	23,926.0	23,922.3
Intangible assets, net	10,271.2	10,429.6
Other assets	359.3	367.8
<b>Total assets</b>	<b>\$ 54,467.0</b>	<b>\$ 54,721.9</b>
<b>Liabilities:</b>		
Accounts payable	\$ 3,287.0	\$ 3,593.0
Claims and discounts payable	2,245.6	2,484.3
Accrued expenses	2,250.9	2,556.8
Short-term debt	980.0	2,085.0
Current portion of long-term debt	47.3	47.2
<b>Total current liabilities</b>	<b>8,810.8</b>	<b>10,766.3</b>
Long-term debt	8,348.3	8,349.7
Deferred income taxes	3,437.7	3,426.1
Other long-term liabilities	860.0	857.9
<b>Shareholders' equity:</b>		
Preference stock, series one ESOP convertible, par value \$1.00: authorized 50,000,000 shares; issued and outstanding 3,702,000 shares at June 28, 2008 and 3,798,000 shares at December 29, 2007	197.9	203.0
Common stock, par value \$0.01: authorized 3,200,000,000 shares; issued 1,601,670,000 shares at June 28, 2008 and 1,590,139,000 shares at December 29, 2007	16.0	15.9
Treasury stock, at cost: 166,130,000 shares at June 28, 2008 and 153,682,000 shares at December 29, 2007	(5,869.6)	(5,620.4)
Shares held in trust, 1,700,000 shares at June 28, 2008 and 9,224,000 shares at December 29, 2008	(55.5)	(301.3)
Guaranteed ESOP obligation	(44.5)	(44.5)
Capital surplus	27,205.6	26,831.9
Retained earnings	11,608.3	10,287.0
Accumulated other comprehensive loss	(48.0)	(49.7)
<b>Total shareholders' equity</b>	<b>33,010.2</b>	<b>31,321.9</b>
<b>Total liabilities and shareholders' equity</b>	<b>\$ 54,467.0</b>	<b>\$ 54,721.9</b>

Edgar Filing: CVS CAREMARK CORP - Form 10-Q

See accompanying notes to consolidated condensed financial statements (unaudited).

**Table of Contents**

Part I

Item 1

**CVS Caremark Corporation**  
**Consolidated Condensed Statements of Cash Flows**  
**(Unaudited)**

<i>(In millions)</i>	<i>26 Weeks Ended</i>	
	<b>June 28, 2008</b>	<b>June 30, 2007</b>
<b>Cash flows from operating activities:</b>		
Cash receipts from revenues	\$ 30,803.6	\$ 28,614.2
Cash paid for inventory	(22,428.1)	(21,836.9)
Cash paid to other suppliers and employees	(5,938.5)	(4,447.7)
Interest received	10.1	15.6
Interest paid	(267.1)	(201.2)
Income taxes paid	(787.9)	(716.8)
<b>Net cash provided by operating activities</b>	<b>1,392.1</b>	<b>1,427.2</b>
<b>Cash flows from investing activities:</b>		
Additions to property and equipment	(955.3)	(778.0)
Proceeds from sale-leaseback transactions	69.6	23.7
Acquisitions (net of cash acquired) and other investments	(14.0)	(1,941.3)
Sale/(purchase) of short-term investments	27.5	(96.0)
Proceeds from sale or disposal of assets	9.5	86.1
<b>Net cash used in investing activities</b>	<b>(862.7)</b>	<b>(2,705.5)</b>
<b>Cash flows from financing activities:</b>		
Reductions in short-term debt	(1,105.0)	(1,182.3)
Dividends paid	(172.1)	(132.4)
Proceeds from exercise of stock options	278.9	231.3
Excess tax benefits from stock based compensation	52.2	30.1
Additions to long-term debt		6,000.0
Reductions in long-term debt	(1.3)	(520.6)
Repurchase of common stock	(23.0)	(2,866.2)
<b>Net cash (used in)/provided by financing activities</b>	<b>(970.3)</b>	<b>1,559.9</b>
Net (decrease)/increase in cash and cash equivalents	(440.9)	281.6
Cash and cash equivalents at beginning of period	1,056.6	530.7
<b>Cash and cash equivalents at end of period</b>	<b>\$ 615.7</b>	<b>\$ 812.3</b>
<b>Reconciliation of net earnings to net cash provided by operating activities:</b>		
Net earnings	\$ 1,523.3	\$ 1,132.5
Adjustments required to reconcile net earnings to net cash provided by operating activities:		
Depreciation and amortization	609.3	516.8
Stock based compensation	35.4	47.0
Deferred income taxes and other non-cash items	(8.1)	(5.3)
Change in operating assets and liabilities, providing/(requiring) cash, net of effects from acquisitions:		



Edgar Filing: CVS CAREMARK CORP - Form 10-Q

Accounts receivable, net	121.9	566.5
Inventories	6.9	(190.9)
Other current assets	(30.3)	(19.9)
Other assets	10.3	(13.1)
Accounts payable and Claims and discounts payable	(544.6)	(291.0)
Accrued expenses	(334.6)	(335.1)
Other long-term liabilities	2.6	19.7
<b>Net cash provided by operating activities</b>	<b>\$ 1,392.1</b>	<b>\$ 1,427.2</b>

See accompanying notes to consolidated condensed financial statements (unaudited).

---

**Table of Contents**

**Part I**

**Item 1**

**CVS Caremark Corporation**

**Notes to Consolidated Condensed Financial Statements**

**(Unaudited)**

**Note 1**

The accompanying consolidated condensed financial statements of CVS Caremark Corporation and its wholly-owned subsidiaries (the Company) have been prepared, in accordance with the rules and regulations of the Securities and Exchange Commission, without audit. In accordance with such rules and regulations, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted, although the Company believes the disclosures included herein are adequate to make the information presented not misleading. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in Exhibit 13 to the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2007 (the 2007 Form 10-K).

The Company adopted Emerging Issues Task Force (EITF) Issue No. 06-4, Accounting for Deferred Compensation and Postretirement Benefit Aspects of Endorsement Split-Dollar Life Insurance Arrangements, at the beginning of fiscal 2008. EITF No. 06-4 requires the application of the provisions of SFAS No. 106, Employers' Accounting for Postretirement Benefits Other Than Pensions (SFAS 106) (if, in substance, a postretirement benefit plan exists), or Accounting Principles Board Opinion No. 12 (if the arrangement is, in substance, an individual deferred compensation contract) to endorsement split-dollar life insurance arrangements. SFAS 106 requires us to recognize a liability for the discounted value of the future premium benefits that we will incur through the death of the underlying insureds. The adoption of EITF No. 06-4 did not have a material impact on the Company's consolidated results of operations, financial position and cash flows.

The Company adopted EITF No. 06-10, Accounting for Collateral Assignment Split-Dollar Life Insurance Agreements, at the beginning of fiscal 2008. EITF No. 06-10 provides guidance for determining a liability for the postretirement benefit obligation as well as recognition and measurement of the associated asset on the basis of the terms of the collateral assignment agreement. The adoption of EITF No. 06-10 did not have a material impact on the Company's consolidated results of operations, financial position and cash flows.

In the opinion of management, the accompanying consolidated condensed financial statements include all adjustments (consisting only of normal recurring adjustments), which are necessary to present a fair statement of the Company's results for the interim periods presented. Because of the influence of various factors on the Company's operations, including business combinations, certain holidays and other seasonal influences, net earnings for any interim period may not be comparable to the same interim period in previous years or necessarily indicative of earnings for the full fiscal year.

**Note 2**

In connection with certain business dispositions completed between 1991 and 1997, the Company continues to guarantee approximately 220 store lease obligations for a number of former subsidiaries, including Linens 'n Things. On May 2, 2008, Linens Holding Co., which operates Linens 'n Things, filed a voluntary petition under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The loss from discontinued operations includes \$78.8 million of lease-related costs (\$48.7 million net of a \$30.1 million income tax benefit), which the Company believes it may be required to satisfy pursuant to the lease guarantees. These amounts, which will change as more information becomes available, were calculated in accordance with Statement of Financial Accounting Standards No. 146, Accounting for Costs Associated with Exit or Disposal Activities. Please see Note 12 to the consolidated condensed financial statements for further information regarding the Company's lease guarantees.

**Table of Contents**

Part I

Item 1

**CVS Caremark Corporation****Notes to Consolidated Condensed Financial Statements****(Unaudited)****Note 3**

Effective March 22, 2007, pursuant to the Agreement and Plan of Merger dated as of November 1, 2006, as amended (the Merger Agreement), Caremark Rx, Inc. (Caremark) was merged with and into a newly formed subsidiary of CVS Corporation, with the CVS subsidiary continuing as the surviving entity (the Caremark Merger). Following the merger, the Company changed its name to CVS Caremark Corporation. The Company believes CVS and Caremark are complementary companies and the combined company can be operated more efficiently than either company could have been operated on its own. The combined company is expected to benefit from its ability to provide efficient cost-management solutions to health plan sponsors and innovative programs to consumers, including expanded choice, improved access and more personalized service.

The merger was accounted for using the purchase method of accounting under U.S. Generally Accepted Accounting Principles. Under the purchase method of accounting, CVS Corporation was considered the acquirer of Caremark for accounting purposes and the total purchase price has been allocated to the assets acquired and liabilities assumed from Caremark based on their fair values as of March 22, 2007. The difference between the total purchase price and the amounts allocated to the assets acquired and liabilities assumed, discussed below, was recognized as goodwill in accordance with Statement of Financial Accounting Standards (SFAS) No. 141, Business Combinations.

Following is a summary of the assets acquired and liabilities assumed as of March 22, 2007.

**Assets Acquired and Liabilities Assumed as of March 22, 2007***(In millions)*

Cash and cash equivalents	\$ 1,293.4
Short-term investments	27.5
Accounts receivable	2,472.7
Inventories	442.3
Deferred tax asset	95.4
Other current assets	31.2
<b>Total current assets</b>	<b>4,362.5</b>
Property and equipment <sup>(1)</sup>	305.3
Goodwill	20,881.4
Intangible assets <sup>(2)</sup>	9,319.7
Other assets	67.2
<b>Total assets acquired</b>	<b>34,936.1</b>
Accounts payable	960.8
Claims and discounts payable	2,430.1
Accrued expenses <sup>(3)</sup>	1,020.0
<b>Total current liabilities</b>	<b>4,410.9</b>
Deferred tax liability	3,581.4
Other long-term liabilities	93.2

<b>Total liabilities assumed</b>	<b>8,085.5</b>
<b>Net assets acquired</b>	<b>\$ 26,850.6</b>

**Table of Contents**

Part I

Item 1

## CVS Caremark Corporation

## Notes to Consolidated Condensed Financial Statements

(Unaudited)

- (1) Property and equipment includes proprietary technology (\$108.1 million) with an estimated weighted average life of 3.5 years.
- (2) Intangible assets include customer contracts and relationships (\$2.9 billion) with an estimated weighted average life of 14.7 years, favorable leaseholds (\$12.7 million) with an estimated weighted average life of 6.2 years, covenants not to compete (\$9.0 million) with an estimated average life of 2 years and trade names (\$6.4 billion), which are indefinitely lived.
- (3) Accrued expenses include \$54.0 million for estimated severance, benefits and outplacement costs for approximately 340 Caremark employees, substantially all of whom had been terminated as of June 28, 2008. As of June 28, 2008, \$48.9 million of the liability has been settled with cash payments. The remaining liability will require future cash payments through 2009. Accrued expenses also include \$1.5 million for the estimated costs associated with the non-cancelable lease obligation of two locations. As of June 28, 2008, \$1.0 million of the liability has been settled with cash payments. The remaining liability will require future cash payments through 2009.

**THE FOLLOWING PRO FORMA COMBINED RESULTS OF OPERATIONS HAVE BEEN PROVIDED FOR ILLUSTRATIVE PURPOSES ONLY AND DO NOT PURPORT TO BE INDICATIVE OF THE ACTUAL RESULTS THAT WOULD HAVE BEEN ACHIEVED BY THE COMBINED COMPANY FOR THE PERIODS PRESENTED OR THAT WILL BE ACHIEVED BY THE COMBINED COMPANY IN THE FUTURE:**

<i>(In millions, except per share amounts)</i>	<i>26 Weeks Ended</i>
	<b>June 30, 2007</b>
Pro forma:	
Net revenues	\$ 41,361.0
Net earnings	1,386.0
Basic earnings per share	\$ 0.91
Diluted earnings per share	0.89

- (1) The pro forma combined results of operations assume that the Caremark Merger occurred at the beginning of the period presented. These results have been prepared by adjusting the historical results of the Company to include the historical results of Caremark, incremental interest expense and the impact of the purchase price allocation discussed above.
- (2) Inter-company revenues that occur when a Caremark customer uses a CVS/pharmacy retail store to purchase covered merchandise were eliminated. These adjustments had no impact on pro forma net earnings or pro forma earnings per share.
- (3) The pro forma combined results of operations do not include any cost savings that may result from the combination of the Company and Caremark or any estimated costs that will be incurred by the Company to integrate the businesses.

- (4) The pro forma combined results of operations for the twenty-six weeks ended June 30, 2007, exclude \$80.3 million pre-tax (\$48.4 million after-tax) of stock option expense associated with the accelerated vesting of certain Caremark stock options, which vested upon consummation of the merger due to change in-control provisions of the underlying Caremark stock option plans. The pro forma combined results for the twenty-six weeks ended June 30, 2007 also exclude \$42.9 million pre-tax (\$25.9 million after-tax) related to change in control payments due upon the consummation of the merger due to change-in-control provisions in certain Caremark employment agreements. In addition, the pro forma combined results of operations for the twenty-six weeks ended June 30, 2007, exclude merger related costs of \$110.9 million pre-tax (\$78.0 million after-tax), which primarily consist of investment banker fees, legal fees, accounting fees and other merger related costs incurred by Caremark.

---

**Table of Contents**

**Part I**

**Item 1**

**CVS Caremark Corporation**

**Notes to Consolidated Condensed Financial Statements**

**(Unaudited)**

**Note 4**

On November 6, 2007, the Company entered into a \$2.3 billion fixed dollar accelerated share repurchase agreement (the November ASR agreement) with Lehman Brothers, Inc. (Lehman). The November ASR agreement contained provisions that established the minimum and maximum number of shares to be repurchased during the term of the November ASR agreement. Pursuant to the terms of the November ASR agreement, on November 7, 2007, the Company paid \$2.3 billion to Lehman in exchange for Lehman delivering 37.2 million shares of common stock to the Company. On November 26, 2007, upon establishment of the minimum number of shares to be repurchased, Lehman delivered an additional 14.4 million shares of common stock to the Company. The aggregate 51.6 million shares of common stock delivered to the Company by Lehman were placed into the Company's treasury account. The final settlement under the November ASR program occurred on March 28, 2008 and resulted in the Company receiving an additional 5.7 million shares of common stock during the first quarter of 2008, which were placed into the Company's treasury account upon delivery.

On May 7, 2008, the Company's Board of Directors authorized, effective May 21, 2008, a share repurchase program for up to \$2.0 billion of outstanding common stock. The specific timing and amount of repurchases will vary based on market conditions and other factors. During the second quarter ended June 28, 2008, the Company repurchased 0.6 million shares of common stock for \$23.0 million. The shares were placed into the Company's treasury account upon delivery. The stock repurchase program may be modified, extended or terminated by the Board of Directors at any time.

**Note 5**

The Company currently operates two business segments: Retail Pharmacy and Pharmacy Services. The operating segments are businesses of the Company for which separate financial information is available and for which operating results are evaluated on a regular basis by executive management in deciding how to allocate resources and in assessing performance. The Company's business segments offer different products and services and require distinct technology and marketing strategies.

As of June 28, 2008, the Retail Pharmacy Segment included 6,308 retail drugstores, the Company's online retail website, CVS.com® and its retail healthcare clinics. The retail drugstores are located in 40 states and the District of Columbia and operate under the CVS® or CVS/pharmacy® name. The retail healthcare clinics utilize nationally recognized medical protocols to diagnose and treat minor health conditions and are staffed by board-certified nurse practitioners and physician assistants. The retail healthcare clinics operate under the MinuteClinic® name and as of June 28, 2008, included 516 clinics located in 25 states, 495 of these clinics are located within the Company's retail drugstores.

The Pharmacy Services Segment provides a full range of pharmacy benefit management services to employers, managed care providers and other organizations. These services include mail order pharmacy services, specialty pharmacy services, plan design and administration, formulary management and claims processing, as well as providing insurance and reinsurance services in conjunction with prescription drug benefit plans. The specialty pharmacy business focuses on supporting individuals that require complex and expensive drug therapies. Currently, the Pharmacy Services segment operates under the Caremark Pharmacy Services®, Caremark Specialty Pharmacy®, CarePlus Pharmacy®, PharmaCare Management Services®, and PharmaCare Pharmacy® names. As of June 28, 2008, the Pharmacy Services Segment included 56 retail specialty drugstores, 19 specialty mail order pharmacies and 7 mail service pharmacies located in 26 states and the District of Columbia.

**Table of Contents**

Part I

Item 1

## CVS Caremark Corporation

## Notes to Consolidated Condensed Financial Statements

(Unaudited)

The Company evaluates segment performance based on net revenues, gross profit and operating profit before the effect of discontinued operations and certain intersegment activities and charges.

Following is a reconciliation of the Company's business segments to the accompanying consolidated condensed financial statements:

<i>(In millions)</i>	Retail Pharmacy Segment	Pharmacy Services Segment <sup>(1)</sup>	Intersegment Eliminations <sup>(2)</sup>	Consolidated Totals
<i>13 weeks ended:</i>				
<b>June 28, 2008:</b>				
Net revenues	\$ 11,770.8	\$ 10,656.8	\$ (1,287.3)	\$ 21,140.3
Gross profit	3,523.3	849.9		4,373.2
Operating profit	864.0	614.1		1,478.1
June 30, 2007:				
Net revenues	\$ 11,249.7	\$ 10,554.1	\$ (1,100.5)	\$ 20,703.3
Gross profit	3,295.7	862.8		4,158.5
Operating profit	727.8	582.0		1,309.8
<i>26 weeks ended:</i>				
<b>June 28, 2008:</b>				
Net revenues	\$ 23,616.4	\$ 21,421.5	\$ (2,571.6)	\$ 42,466.3
Gross profit	7,028.3	1,637.9		8,666.2
Operating profit	1,704.1	1,144.1		2,848.2
June 30, 2007:				
Net revenues	\$ 22,488.9	\$ 12,664.4	\$ (1,261.4)	\$ 33,891.9
Gross profit	6,401.4	1,060.3		7,461.7
Operating profit	1,353.7	692.6		2,046.3
Total assets:				
<b>June 28, 2008</b>	<b>\$ 20,223.8</b>	<b>\$ 34,497.4</b>	<b>\$ (254.2)</b>	<b>\$ 54,467.0</b>
December 29, 2007	19,962.6	35,015.1	(255.8)	54,721.9
Goodwill:				
<b>June 28, 2008</b>	<b>\$ 2,585.4</b>	<b>\$ 21,340.6</b>	<b>\$</b>	<b>\$ 23,926.0</b>
December 29, 2007	2,585.7	21,336.6		23,922.3

- (1) Net revenues of the Pharmacy Services Segment include approximately \$1,540.2 million and \$1,412.1 million of Retail Co-payments for the thirteen weeks ended June 28, 2008 and June 30, 2007, respectively. Net revenues of the Pharmacy Services Segment include approximately \$3,205.1 million and \$1,568.1 million of Retail Co-payments for the twenty- six weeks ended June 28, 2008 and June 30, 2007, respectively.



## Edgar Filing: CVS CAREMARK CORP - Form 10-Q

- (2) Intersegment eliminations relate to intersegment revenues and accounts receivables that occur when a Pharmacy Services Segment customer uses a Retail Pharmacy Segment store to purchase covered products. When this occurs, both segments record the revenue on a stand-alone basis.

**Table of Contents****Part I****Item 1****CVS Caremark Corporation****Notes to Consolidated Condensed Financial Statements****(Unaudited)****Note 6**

The Company accounts for goodwill and intangible assets under SFAS No. 142, Goodwill and Other Intangible Assets. As such, goodwill and other indefinitely-lived intangible assets are not amortized, but are subject to annual impairment reviews, or more frequent reviews if events or circumstances indicate there may be an impairment. During the third quarter of 2007, the Company performed its required annual goodwill impairment test, which concluded there was no impairment of goodwill.

The carrying amount of goodwill was \$23.9 billion at June 28, 2008 and December 29, 2007. There has been no impairment of goodwill during the twenty-six weeks ended June 28, 2008. The carrying amount of indefinitely-lived assets was \$6.4 billion as of June 28, 2008 and December 29, 2007. Intangible assets with finite useful lives are amortized over their estimated useful life.

Following is a summary of the Company's intangible assets as of the respective balance sheet dates:

<i>(In millions)</i>	<i>As of June 28, 2008</i>		<i>As of December 29, 2007</i>	
	<b>Gross Carrying Amount</b>	<b>Accumulated Amortization</b>	<b>Gross Carrying Amount</b>	<b>Accumulated Amortization</b>
Trademarks (indefinitely-lived)	\$ 6,398.0	\$	\$ 6,398.0	\$
Customer relationships and Covenants not to compete	4,471.4	(1,050.8)	4,444.1	(876.9)
Favorable leases and Other	628.6	(176.0)	623.0	(158.6)
	<b>\$ 11,498.0</b>	<b>\$ (1,226.8)</b>	<b>\$ 11,465.1</b>	<b>\$ (1,035.5)</b>

The amortization expense related to finite-lived intangible assets for the thirteen and twenty-six weeks ended June 28, 2008 was \$97.8 million and \$195.7 million, respectively. The anticipated annual amortization expense for these intangible assets is \$390.5 million, \$372.4 million, \$365.5 million, \$356.3 million, \$338.1 million and \$317.9 million in 2008, 2009, 2010, 2011, 2012 and 2013, respectively.

**Note 7**

Accumulated other comprehensive loss consists of changes in the net actuarial gains and losses associated with pension and other post retirement benefit plans, unrealized losses on derivatives and adjustment to initially apply SFAS No. 158, Employers Accounting for Defined Benefit Pension and Other Postretirement Plans. In accordance with SFAS No. 158, the amount included in accumulated other comprehensive income related to the Company's pension and post retirement plans was \$58.7 million pre-tax (\$35.9 million after-tax) as of June 28, 2008 and December 29, 2007. The unrealized loss on derivatives totaled \$19.2 million pre-tax (\$12.1 million after-tax) and \$21.9 million pre-tax (\$13.8 million after-tax) as of June 28, 2008 and December 29, 2007, respectively.

**Table of Contents****Part I****Item 1****CVS Caremark Corporation****Notes to Consolidated Condensed Financial Statements****(Unaudited)**

Following are the changes in comprehensive income:

<i>(In millions)</i>	<i>13 weeks ended</i>		<i>26 weeks ended</i>	
	<b>June 28, 2008</b>	June 30, 2007	<b>June 28, 2008</b>	June 30, 2007
Net earnings, as reported	<b>\$ 774.8</b>	\$ 723.6	<b>\$ 1,523.3</b>	\$ 1,132.5
Other comprehensive loss:				
Reclassification of unrealized loss on derivatives, net of taxes	<b>0.8</b>	0.8	<b>1.7</b>	1.6
Total comprehensive income, net of taxes	<b>\$ 775.6</b>	\$ 724.4	<b>\$ 1,525.0</b>	\$ 1,134.1

As of June 28, 2008, the Company had no freestanding derivatives in place.

**Note 8**

The Company accounts for stock-based compensation in accordance with Statement of Financial Accounting Standards No. 123 (revised 2004), Share-Based Payment (SFAS 123(R)). Compensation expense related to stock options, which includes the 1999 Employee Stock Purchase Plan (1999 ESPP) and the 2007 Employee Stock Purchase Plan (2007 ESPP) and collectively (the ESPP) for the thirteen and twenty-six weeks ended June 28, 2008 totaled \$27.1 million and \$47.8 million, respectively. Compensation expense related to stock options for the thirteen and twenty-six weeks ended June 30, 2007 totaled \$22.2 million and \$35.3 million, respectively. Compensation expense related to restricted stock awards for the thirteen and twenty-six weeks ended June 28, 2008, totaled \$6.9 million and \$14.0 million, respectively, compared to \$5.5 million and \$15.7 million for the thirteen and twenty-six weeks ended June 30, 2007. During the thirteen weeks ended June 28, 2008, the Company granted 12.1 million stock options with a weighted average fair value of \$8.67 under the Company's 1997 Incentive Compensation Plan. In accordance with SFAS 123(R), compensation expense is recognized on a straight-line basis over the employee's vesting period or to the employee's retirement eligible date, if earlier.

**Note 9**

Following are the components of net interest expense:

<i>(In millions)</i>	<i>13 weeks ended</i>		<i>26 weeks ended</i>	
	<b>June 28, 2008</b>	June 30, 2007	<b>June 28, 2008</b>	June 30, 2007
Interest expense	<b>\$ 118.5</b>	\$ 113.8	<b>\$ 255.7</b>	\$ 185.4
Interest income	<b>(3.8)</b>	(7.9)	<b>(10.1)</b>	(15.6)
Interest expense, net	<b>\$ 114.7</b>	\$ 105.9	<b>\$ 245.6</b>	\$ 169.8

**Note 10**

As a result of the Caremark Merger, the Company acquired certain grantor trusts, which as of the 2007 fiscal year end held approximately 9.2 million shares of its common stock designated for use under various employee compensation plans. During the twenty-six week period ended June 28, 2008, the Company transferred 7.5 million shares of the common stock held by the grantor trusts to the Company's treasury account. As of June 28, 2008, the grantor trusts held approximately 1.7 million of the Company's common stock. Since the Company holds the

shares in the grantor trusts, they are excluded from the computation of basic and diluted shares outstanding.

**Table of Contents**

**Part I**

**Item 1**

**CVS Caremark Corporation**

**Notes to Consolidated Condensed Financial Statements**

**(Unaudited)**

**Note 11**

Basic earnings per common share is computed by dividing: (i) net earnings, after deducting the after-tax Employee Stock Ownership Plan ( ESOP ) preference dividends, by (ii) the weighted average number of common shares outstanding during the period (the Basic Shares ).

When computing diluted earnings per common share, the Company assumes the ESOP preference stock is converted into common stock and all dilutive stock awards are exercised. After the assumed ESOP preference stock conversion, the ESOP Trust would hold common stock rather than ESOP preference stock and would receive common stock dividends (\$0.25800 and \$0.22875 annually per share in 2008 and 2007, respectively) rather than ESOP preference stock dividends (currently \$3.90 annually per share). Since the ESOP Trust uses the dividends it receives to service its debt, the Company would have to increase its contribution to the ESOP Trust to compensate it for the lower dividends. This additional contribution would reduce the Company s net earnings, which in turn, would reduce the amounts that would have to be accrued under the Company s incentive compensation plans.

Diluted earnings per common share is computed by dividing: (i) net earnings, after accounting for the difference between the dividends on the ESOP preference stock and common stock and after making adjustments for the incentive compensation plans, by (ii) Basic Shares plus the additional shares that would be issued assuming that all dilutive stock awards are exercised and the ESOP preference stock is converted into common stock. Options to purchase 13.2 million and 7.3 million shares of common stock were outstanding but were not included in the calculation of diluted earnings per share for the thirteen and twenty-six weeks ended June 28, 2008, respectively, because the options exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. Similarly, options to purchase 13.2 million and 7.6 million shares of common stock were outstanding but were not included in the calculation of diluted earnings per share for the thirteen and twenty-six weeks ended June 30, 2007, respectively.

**Table of Contents**

Part I

Item 1

## CVS Caremark Corporation

## Notes to Consolidated Condensed Financial Statements

(Unaudited)

Following is a reconciliation of basic and diluted earnings per common share for the respective periods:

<i>(In millions, except per share amounts)</i>	<i>13 weeks ended</i>		<i>26 weeks ended</i>	
	<b>June 28, 2008</b>	June 30, 2007	<b>June 28, 2008</b>	June 30, 2007
<b>Numerator for earnings per common share calculation:</b>				
Earnings from continuing operations	\$ 823.5	\$ 723.6	\$ 1,572.0	\$ 1,132.5
Preference dividends, net of income tax benefit	(3.6)	(3.5)	(7.1)	(7.0)
Earnings from continuing operations available to common shareholders, basic	819.9	720.1	1,564.9	1,125.5
Loss from discontinued operations, net of income tax benefit	(48.7)		(48.7)	
Net earnings available to common shareholders, basic	\$ 771.2	\$ 720.1	\$ 1,516.2	\$ 1,125.5
Earnings from continuing operations	\$ 823.5	\$ 723.6	\$ 1,572.0	\$ 1,132.5
Dilutive earnings adjustments	(1.0)	(0.8)	(1.9)	(1.9)
Earnings from continuing operations available to common shareholders, diluted	822.5	722.8	1,570.1	1,130.6
Loss from discontinued operations, net of income tax benefit	(48.7)		(48.7)	
Net earnings available to common shareholders, diluted	\$ 773.8	\$ 722.8	\$ 1,521.4	\$ 1,130.6
<b>Denominator for earnings per common share calculation:</b>				
Weighted average common shares, basic	1,431.8	1,492.4	1,430.8	1,199.2
Effect of dilutive securities:				
Restricted stock units	4.1	3.1	4.1	3.2
ESOP preference stock	17.2	18.1	17.4	18.2
Stock options	15.6	28.9	16.2	20.8
Weighted average common shares, diluted	1,468.7	1,542.5	1,468.5	1,241.4
<b>Basic earnings per common share:</b>				
Earnings from continuing operations	\$ 0.57	\$ 0.48	\$ 1.09	\$ 0.94
Loss from discontinued operations	(0.03)		(0.03)	
Net earnings	\$ 0.54	\$ 0.48	\$ 1.06	\$ 0.94
<b>Diluted earnings per common share:</b>				
Earnings from continuing operations	\$ 0.56	\$ 0.47	\$ 1.07	\$ 0.91
Loss from discontinued operations	(0.03)		(0.03)	

Edgar Filing: CVS CAREMARK CORP - Form 10-Q

Net earnings	\$	<b>0.53</b>	\$	0.47	\$	<b>1.04</b>	\$	0.91
--------------	----	-------------	----	------	----	-------------	----	------

---

**Table of Contents**

**Part I**

**Item 1**

**CVS Caremark Corporation**

**Notes to Consolidated Condensed Financial Statements**

**(Unaudited)**

**Note 12**

Between 1991 and 1997, the Company sold or spun off a number of subsidiaries, including Bob's Stores, Linens 'n Things, Marshalls, Kay-Bee Toys, This End Up and Footstar, which were classified as discontinued operations. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the store's lease obligations. When the subsidiaries were disposed of, the Company's guarantees remained in place, although each initial purchaser has indemnified the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries were to become insolvent and failed to make the required payments under a store lease, the Company could be required to satisfy these obligations. As of December 29, 2007, the Company guaranteed approximately 220 such store leases, with the maximum remaining lease term extending through 2022. Assuming that each respective purchaser became insolvent and the Company was required to assume all of these lease obligations, management estimates that the Company could settle the obligations for approximately \$325 to \$375 million as of December 29, 2007. Management believes the ultimate disposition of any of the guarantees will not have a material adverse effect on the Company's consolidated financial condition, results of operations or future cash flows. Please see Note 2 to the consolidated condensed financial statements for further information regarding the Company's guarantee of Linens 'n Things' store lease obligations.

In December 2007, the Company received a document subpoena from the Office of Inspector General, United States Department of Health and Human Services (OIG), requesting information relating to the processing of Medicaid and other government agency claims on an adjudication platform of AdvancePCS (acquired by Caremark in 2004 and now known as CaremarkPCS, L.L.C.). The Company has initiated discussions with the OIG and with the U.S Department of Justice concerning our government claims processing activities on the two adjudication platforms used by AdvancePCS and one adjudication platform used by PharmaCare. We are also cooperating with the requests for information contained in the document subpoena by producing responsive documents on a rolling basis. We cannot predict with certainty the timing, outcome or consequence of any review of such information.

The Company has been named in a putative class action lawsuit filed in California state court by Gabe Tong, purportedly on behalf of current and former pharmacists working in the Company's California stores. The lawsuit alleges that CVS failed to provide pharmacists in the purported class with meal and rest periods or to pay overtime as required under California law. In October 2007, the Company reached a conditional agreement, subject to the approval by the court, to resolve this matter. In addition, the Company is party to other employment litigation arising in the normal course of its business. The Company cannot predict the outcome of any of these employment litigation matters at this time, however, none of these matters are expected to be material to the company.

In 2006, a number of shareholder derivative lawsuits were filed in the Tennessee state court and the Tennessee federal court against Caremark and various officers and directors of Caremark seeking, among other things, a declaration that the directors breached their fiduciary duties, imposition of a constructive trust upon any illegal profits received by the defendants and punitive and other damages. The cases brought in the Tennessee federal court were consolidated into one action in August 2006, and the consolidated action was voluntarily dismissed without prejudice by the plaintiffs in March 2007. The cases brought in the Tennessee state court were also consolidated into one action, and the plaintiffs amended their complaint to add CVS and its directors as defendants and to allege class action claims.



---

**Table of Contents**

**Part I**

**Item 1**

**CVS Caremark Corporation**

**Notes to Consolidated Condensed Financial Statements**

**(Unaudited)**

A stipulation of settlement was entered into by the parties on July 5, 2007, which provided, among other things, that (i) the plaintiffs will dismiss the case and release the defendants from claims asserted in the action, (ii) a temporary restraining order issued by the court in March 2007 will be vacated, (iii) defendants will agree to maintain for at least four years a number of corporate governance provisions relating to the granting, exercise and disclosure of stock option awards and (iv) the defendants will not oppose plaintiffs' petition for an award of attorneys' fees and expenses not to exceed \$7.5 million. As part of the settlement, the defendants specifically denied any liability or wrongdoing with respect to all claims alleged in the litigation, including claims relating to stock option backdating, and acknowledged that they entered into the settlement solely to avoid the distraction, burden and expense of the pending litigation. On July 14, 2008, the settlement was approved by the trial court.

The Rhode Island Attorney General's Office, the Rhode Island Ethics Commission, and the United States Attorney's Office for the District of Rhode Island have been investigating the business relationships between certain former members of the Rhode Island General Assembly and various Rhode Island companies, including Roger Williams Medical Center, Blue Cross & Blue Shield of Rhode Island and CVS. In connection with the investigation of these business relationships, a former state senator was criminally charged in 2005 by federal and state authorities and has pled guilty to those charges, and a former state representative was criminally charged in October 2007 by federal authorities and has pled guilty to those charges. In January 2007, two CVS employees on administrative leave from the Company were indicted on federal charges relating to their involvement in entering into a \$12,000 per year consulting agreement with the former state senator eight years ago. In May 2008, after a jury trial, both employees were acquitted of all charges. CVS will continue to cooperate fully in this investigation, the timing and outcome of which cannot be predicted with certainty at this time.

Caremark's subsidiary Caremark, Inc. (now known as Caremark, L.L.C.) is a defendant in a qui tam lawsuit initially filed by a relator on behalf of various state and federal government agencies in Texas federal court in 1999. The case was unsealed in May 2005. The case seeks money damages and alleges that Caremark's processing of Medicaid and certain other government claims on behalf of its clients violates applicable federal or state false claims acts and fraud statutes. The U.S. Department of Justice and the States of Texas, Tennessee, Florida, Arkansas, Louisiana and California intervened in the lawsuit, but Tennessee and Florida withdrew from the lawsuit in August 2006 and May 2007, respectively. A phased approach to discovery is ongoing. The parties have filed cross motions for partial summary judgment, argued those motions before the court and final rulings are pending.

Caremark was named in a putative class action lawsuit filed on October 22, 2003 in Alabama state court by John Lauriello, purportedly on behalf of participants in the 1999 settlement of various securities class action and derivative lawsuits against Caremark and others. Other defendants include insurance companies that provided coverage to Caremark with respect to the settled lawsuits. The Lauriello lawsuit seeks approximately \$3.2 billion in compensatory damages plus other non-specified damages based on allegations that the amount of insurance coverage available for the settled lawsuits was misrepresented and suppressed. A similar lawsuit was filed on November 5, 2003, by Frank McArthur, also in Alabama state court, naming as defendants Caremark, several insurance companies, attorneys and law firms involved in the 1999 settlement. This lawsuit was subsequently stayed by the court as a later-filed class action. McArthur sought to intervene in the Lauriello action, and proceedings are currently stayed pending an appeal by McArthur of certain rulings relating to his complaint in intervention.

---

**Table of Contents**

**Part I**

**Item 1**

**CVS Caremark Corporation**

**Notes to Consolidated Condensed Financial Statements**

**(Unaudited)**

Various lawsuits have been filed alleging that Caremark and its subsidiaries Caremark Inc. (now known as Caremark, L.L.C.) and AdvancePCS (now known as CaremarkPCS, L.L.C.) have violated applicable antitrust laws in establishing and maintaining retail pharmacy networks for client health plans. In August 2003, Bellevue Drug Co., Robert Schreiber, Inc. d/b/a Burns Pharmacy and Rehn-Huerbinger Drug Co. d/b/a Parkway Drugs #4, together with Pharmacy Freedom Fund and the National Community Pharmacists Association filed a putative class action against AdvancePCS in Pennsylvania federal court, seeking treble damages and injunctive relief. The claims were initially sent to arbitration based on contract terms between the pharmacies and AdvancePCS. In October 2003, two independent pharmacies, North Jackson Pharmacy, Inc. and C&C, Inc. d/b/a Big C Discount Drugs, Inc. filed a putative class action complaint in Alabama federal court against Caremark, Caremark Inc. AdvancePCS and two PBM competitors, seeking treble damages and injunctive relief. The case against Caremark and Caremark Inc. was transferred to Illinois federal court, and the AdvancePCS case was sent to arbitration based on contract terms between the pharmacies and AdvancePCS. The arbitration was then stayed by the parties pending developments in Caremark's court case. In August 2006, the Bellevue case and the North Jackson Pharmacy case were transferred to Pennsylvania federal court by the Judicial Panel on Multidistrict Litigation for coordinated and consolidated proceedings with other cases before the panel, including cases against other PBMs. Caremark has appealed a decision which vacated the order compelling arbitration and staying the proceedings in the Bellevue case to the Third Circuit Court of Appeals. Motions for class certification in the coordinated cases within the multidistrict litigation, including the North Jackson Pharmacy case, remain pending. The consolidated action is now known as the In Re Pharmacy Benefit Managers Antitrust Litigation.

Caremark and its subsidiaries Caremark Inc. (now known as Caremark, L.L.C.) and AdvancePCS (now known as CaremarkPCS, L.L.C.) have been named in a putative class action lawsuit filed in March 2003 in a California state court by an individual named Robert Irwin, purportedly on behalf of California members of non-ERISA health plans and/or all California taxpayers. The lawsuit, which also names other PBMs as defendants, alleges violations of California's unfair competition laws and challenges alleged business practices of PBMs, including practices relating to pricing, rebates, formulary management, data utilization and accounting and administrative processes. Discovery in the case is ongoing.

The Company is also a party to other litigation arising in the normal course of its business, none of which is expected to be material to the Company. The Company can give no assurance, however, that our operating results and financial condition will not be materially adversely affected, or that we will not be required to materially change our business practices, based on: (i) future enactment of new healthcare or other laws or regulations; (ii) the interpretation or application of existing laws or regulations, as they may relate to our business or the pharmacy services industry; (iii) pending or future federal or state governmental investigations of our business or the pharmacy services industry; (iv) institution of government enforcement actions against us; (v) adverse developments in any pending qui tam lawsuit against us, whether sealed or unsealed, or in any future qui tam lawsuit that may be filed against us; or (vi) adverse developments in other pending or future legal proceedings against us or affecting the pharmacy services industry.

**Table of Contents**

**Part I**

**Item 1**

**Report of Independent Registered Public Accounting Firm**

The Board of Directors and Shareholders

CVS Caremark Corporation:

We have reviewed the accompanying consolidated condensed balance sheet of CVS Caremark Corporation and subsidiaries as of June 28, 2008, and the related consolidated condensed statement of operations and cash flows for the thirteen and twenty-six week periods then ended. These financial statements are the responsibility of the Company's management. The consolidated condensed balance sheet of CVS Caremark Corporation and subsidiaries as of June 30, 2007, and for the thirteen and twenty-six week periods then ended were reviewed by other accountants whose report (dated August 6, 2007) stated that they were not aware of any material modifications that should be made to those statements for them to be in conformity with U.S. generally accepted accounting principles.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the accompanying financial statements at June 28, 2008, and for the thirteen and twenty-six week periods then ended for them to be in conformity with U.S. generally accepted accounting principles.

As discussed in Note 1 to the consolidated condensed financial statements, effective December 30, 2007, CVS Caremark Corporation adopted Emerging Issues Task Force (EITF) No. 06-4, *Accounting for Deferred Compensation and Postretirement Benefit Aspects of Endorsement Split-Dollar Life Insurance Arrangements* and EITF No. 06-10, *Accounting for Collateral Assignment Split-Dollar Life Insurance Arrangements*.

July 28, 2008

/s/ Ernst & Young LLP

Boston, Massachusetts

**Table of Contents**

**Part I**

**Item 2**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Overview of Our Business**

CVS Caremark is the largest provider of prescriptions in the United States. We fill or manage more than one billion prescriptions annually. As a fully integrated pharmacy services company, we drive value for our customers by effectively managing pharmaceutical costs and improving healthcare outcomes through our over 6,300 CVS/pharmacy® stores; our pharmacy benefit management, mail order and specialty pharmacy division, Caremark Pharmacy Services®; our retail healthcare clinic subsidiary, MinuteClinic®; and our online pharmacy, CVS.com®.

Today's healthcare delivery system is rapidly changing. Healthcare is becoming more consumer-centric as the U.S. healthcare system strains to manage growing costs and employers shift more responsibility for managing costs to employees. In addition, an aging population, increasing incidence of chronic disease and increasing utilization of the Medicare drug benefit is fueling demand for prescriptions and pharmacy services. Further, cost-effective generic drugs are becoming more widely available and new drug therapies to treat unmet healthcare needs and reduce hospital stays are being introduced. Consumers require medication management programs and better information to help them get the most out of their healthcare dollars. As a fully integrated pharmacy services company, we are well positioned to provide solutions that address these trends and improve the pharmacy services experience for consumers.

We also strive to improve clinical outcomes, resulting in better control over healthcare costs for employers and health plans. In that regard, we offer a broad spectrum of disease management, health assessment and wellness services to help plan participants manage and protect against potential health risks and avoid future health costs.

Our business is comprised of two operating segments: Retail Pharmacy and Pharmacy Services.

**Results of Operations**

The following discussion explains the material changes in our results of operations for the thirteen and twenty-six weeks ended June 28, 2008 and June 30, 2007 and the significant developments affecting our financial condition since December 29, 2007. We strongly recommend that you read our audited consolidated financial statements and footnotes and Management's Discussion and Analysis of Financial Condition and Results of Operations included as Exhibit 13 to our annual report on Form 10-K for the fiscal year ended December 29, 2007 (the 2007 Form 10-K ) along with this report.

Effective March 22, 2007, we completed our merger with Caremark Rx, Inc. ( Caremark ). Following the merger with Caremark (the Caremark Merger ), we changed our name to CVS Caremark Corporation. Accordingly, our results of operations for the thirteen and twenty-six weeks ended June 30, 2007 include 91 and 101 days, respectively, of post-merger Caremark operations.

**Table of Contents****Part I****Item 2****Management's Discussion and Analysis of Financial Condition and Results of Operations****Second Quarter (Thirteen and Twenty-Six Weeks Ended June 28, 2008 and June 30, 2007)****Summary of the Consolidated Financial Results:**

<i>(In millions, except per share amounts)</i>	<i>13 weeks ended</i>		<i>26 weeks ended</i>	
	<b>June 28, 2008</b>	June 30, 2007	<b>June 28, 2008</b>	June 30, 2007
Net revenues	<b>\$ 21,140.3</b>	\$ 20,703.3	<b>\$ 42,466.3</b>	\$ 33,891.9
Gross profit	<b>4,373.2</b>	4,158.5	<b>8,666.2</b>	7,461.7
Operating expenses	<b>2,895.1</b>	2,848.7	<b>5,818.0</b>	5,415.4
Operating profit	<b>1,478.1</b>	1,309.8	<b>2,848.2</b>	2,046.3
Interest expense, net	<b>114.7</b>	105.9	<b>245.6</b>	169.8
Earnings from continuing operations before income tax provision	<b>1,363.4</b>	1,203.9	<b>2,602.6</b>	1,876.5
Income tax provision	<b>539.9</b>	480.3	<b>1,030.6</b>	744.0
Earnings from continuing operations	<b>823.5</b>	723.6	<b>1,572.0</b>	1,132.5
Loss from discontinued operations, net of income tax benefit	<b>(48.7)</b>		<b>(48.7)</b>	
Net earnings	<b>774.8</b>	723.6	<b>1,523.3</b>	1,132.5
Diluted earnings per common share:				
Earnings from continuing operations	<b>\$ 0.56</b>	\$ 0.47	<b>\$ 1.07</b>	\$ 0.91
Loss from discontinued operations	<b>(0.03)</b>		<b>(0.03)</b>	
Diluted net earnings per common share	<b>\$ 0.53</b>	\$ 0.47	<b>\$ 1.04</b>	\$ 0.91

**Net revenues** increased \$437.0 million and \$8.6 billion during the thirteen and twenty-six weeks ended June 28, 2008, respectively. The increase during the thirteen weeks ended June 28, 2008, was primarily due to increased sales in the Retail Pharmacy segment. The increase during the twenty-six weeks ended June 28, 2008 was primarily due to the Caremark Merger, which resulted in an increase in Pharmacy Services revenue of \$7.9 billion.

**Gross profit** increased \$214.7 million and \$1.2 billion during the thirteen and twenty-six weeks ended June 28, 2008, respectively. The increase during the thirteen and twenty six weeks ended June 28, 2008, was primarily due to increased utilization of generic drugs (which normally yield a higher gross profit rate than equivalent brand name drugs) in both the Retail Pharmacy and Pharmacy Services segments. In addition, the twenty-six weeks ended June 28, 2008 was significantly impacted by the Caremark merger, including benefits from purchasing synergies.

**Operating expenses** increased \$46.4 million and \$402.6 million during the thirteen and twenty-six weeks ended June 28, 2008, respectively. The increase primarily relates to the Caremark Merger, which resulted in incremental amortization related to the intangible assets acquired and merger-related integration costs.

**Table of Contents****Part I****Item 2****Management's Discussion and Analysis of Financial Condition and Results of Operations**

*Interest expense, net* consisted of the following:

<i>(In millions)</i>	<i>13 weeks ended</i>		<i>26 weeks ended</i>	
	<b>June 28, 2008</b>	June 30, 2007	<b>June 28, 2008</b>	June 30, 2007
Interest expense	<b>\$ 118.5</b>	\$ 113.8	<b>\$ 255.7</b>	\$ 185.4
Interest income	<b>(3.8)</b>	(7.9)	<b>(10.1)</b>	(15.6)
<b>Interest expense, net</b>	<b>\$ 114.7</b>	\$ 105.9	<b>\$ 245.6</b>	\$ 169.8

The increase in interest expense during the thirteen and twenty-six weeks ended June 28, 2008 is due to an increase in our average debt balance, which resulted primarily from the borrowings used to fund a special cash dividend paid to Caremark shareholders upon closing of the Caremark Merger and the accelerated share repurchase program that commenced subsequent to the Caremark Merger.

*Income tax provision* ~ Our effective income tax rate was 39.6% for the thirteen and twenty-six weeks ended June 28, 2008, respectively, compared to 39.9% and 39.7% for the comparable 2007 periods. The decrease in our effective income tax rate was primarily due to a reduction in nondeductible items and state taxes.

*Earnings from continuing operations* for thirteen weeks ended June 28, 2008 increased \$99.9 million, or 13.8%, to \$823.5 million (or \$0.56 per diluted share), compared to \$723.6 million (or \$0.47 per diluted share), in the comparable 2007 period. Earnings from continuing operations for twenty-six weeks ended June 28, 2008 increased \$439.5 million, or 38.8%, to \$1,572.0 million (or \$1.07 per diluted share), compared to \$1,132.5 million (or \$0.91 per diluted share) in the comparable 2007 period.

*Loss from discontinued operations* ~ In connection with certain business dispositions completed between 1991 and 1997, we continue to guarantee approximately 220 store lease obligations for a number of former subsidiaries, including Linens n Things. On May 2, 2008, Linens Holding Co., which operates Linens n Things, filed a voluntary petition under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The loss from discontinued operations includes \$78.8 million of lease-related costs (\$48.7 million net of a \$30.1 million income tax benefit), which the Company believes it may be required to satisfy pursuant to the lease guarantees. These amounts, which will change as more information becomes available, were calculated in accordance with Statement of Financial Accounting Standards No. 146, Accounting for Costs Associated with Exit or Disposal Activities.

**Table of Contents****Part I****Item 2****Management's Discussion and Analysis of Financial Condition and Results of Operations****Segment Analysis:**

We evaluate segment performance based on net revenues, gross profit and operating profit before the effect of discontinued operations and certain intersegment activities and charges. Following is a reconciliation of the Company's business segments to the consolidated financial statements:

<i>(In millions)</i>	<b>Retail Pharmacy Segment</b>	<b>Pharmacy Services Segment <sup>(1)</sup></b>	<b>Intersegment Eliminations <sup>(2)</sup></b>	<b>Consolidated Totals</b>
<i>13 weeks ended:</i>				
<b>June 28, 2008:</b>				
Net revenues	\$ 11,770.8	\$ 10,656.8	\$ (1,287.3)	\$ 21,140.3
Gross profit	3,523.3	849.9		4,373.2
Operating profit	864.0	614.1		1,478.1
<i>June 30, 2007:</i>				
Net revenues	\$ 11,249.7	\$ 10,554.1	\$ (1,100.5)	\$ 20,703.3
Gross profit	3,295.7	862.8		4,158.5
Operating profit	727.8	582.0		1,309.8
<i>26 weeks ended:</i>				
<b>June 28, 2008:</b>				
Net revenues	\$ 23,616.4	\$ 21,421.5	\$ (2,571.6)	\$ 42,466.3
Gross profit	7,028.3	1,637.9		8,666.2
Operating profit	1,704.1	1,144.1		2,848.2
<i>June 30, 2007:</i>				
Net revenues	\$ 22,488.9	\$ 12,664.4	\$ (1,261.4)	\$ 33,891.9
Gross profit	6,401.4	1,060.3		7,461.7
Operating profit	1,353.7	692.6		2,046.3

(1) Net revenues of the Pharmacy Services Segment include approximately \$1,540.2 million and \$1,412.1 million of Retail Co-payments for the thirteen weeks ended June 28, 2008 and June 30, 2007, respectively. Net revenues of the Pharmacy Services Segment include approximately \$3,205.1 million and \$1,568.1 million of Retail Co-payments for the twenty-six weeks ended June 28, 2008 and June 30, 2007, respectively.

(2) Intersegment eliminations relate to intersegment revenues and accounts receivables that occur when a Pharmacy Services Segment customer uses a Retail Pharmacy Segment store to purchase covered merchandise. When this occurs, both segments record the revenue on a stand-alone basis.

**Table of Contents****Part I****Item 2****Management's Discussion and Analysis of Financial Condition and Results of Operations****Retail Pharmacy Segment**

The following table summarizes our Retail Pharmacy Segment's performance for the respective periods:

<i>(In millions)</i>	<i>13 Weeks Ended</i>		<i>26 Weeks Ended</i>	
	<b>June 28, 2008</b>	June 30, 2007	<b>June 28, 2008</b>	June 30, 2007
Net revenues	<b>\$ 11,770.8</b>	\$ 11,249.7	<b>\$ 23,616.4</b>	\$ 22,488.9
Gross profit	<b>3,523.3</b>	3,295.7	<b>7,028.3</b>	6,401.4
Gross profit % of net revenues	<b>29.9%</b>	29.3%	<b>29.8%</b>	28.5%
Operating expenses	<b>2,659.3</b>	2,567.9	<b>5,324.2</b>	5,047.7
Operating expense % of net revenues	<b>22.6%</b>	22.8%	<b>22.5%</b>	22.5%
Operating profit	<b>864.0</b>	727.8	<b>1,704.1</b>	1,353.7
Operating profit % of net revenues	<b>7.3%</b>	6.5%	<b>7.2%</b>	6.0%
Net revenue increase:				
Total	<b>4.6%</b>	15.5%	<b>5.0%</b>	19.2%
Pharmacy	<b>4.9%</b>	14.1%	<b>4.9%</b>	17.6%
Front Store	<b>4.1%</b>	18.6%	<b>5.3%</b>	22.6%
Same store sales increase: <sup>(1)</sup>				
Total	<b>3.1%</b>	5.7%	<b>3.5%</b>	6.5%
Pharmacy	<b>3.7%</b>	5.7%	<b>3.7%</b>	6.7%
Front Store	<b>1.8%</b>	5.9%	<b>3.1%</b>	6.2%
Generic dispensing rate	<b>67.0%</b>	62.4%	<b>66.8%</b>	62.1%
Pharmacy % of total revenues	<b>67.8%</b>	67.6%	<b>68.0%</b>	68.1%
Third party % of pharmacy revenue	<b>95.8%</b>	95.0%	<b>95.8%</b>	95.1%
Retail prescriptions filled	<b>134.6</b>	130.7	<b>274.1</b>	264.7

- (1) On June 2, 2006, we acquired certain assets and assumed certain liabilities from Albertson's, Inc. for \$4.0 billion. The assets acquired and the liabilities assumed included approximately 700 standalone drugstores and a distribution center located in La Habra, California (collectively, the Standalone Drug Business). During the thirteen and twenty-six weeks ended June 30, 2007, total net revenues were significantly affected by the acquisition of the Standalone Drug Business, which increased total net revenues by approximately 8.1% and 11.0% respectively. The sales results of the Standalone Drug Business were not included in same store sales revenue until July 1, 2007.

**Net revenues** ~ As you review our Retail Pharmacy Segment's performance in this area, we believe you should consider the following important information:

Front store revenues for the thirteen weeks ended June 28, 2008, were negatively impacted by an earlier Easter (March 23<sup>rd</sup> this year versus April 8<sup>th</sup> last year), which shifted more holiday sales into the first quarter. We estimate the Easter shift decreased total same store revenues by approximately 40 basis points and front store same store revenues by approximately 110 basis points during the thirteen weeks ended June 28, 2008. The Easter shift had no impact on the twenty-six weeks ended June 28, 2008.

As of June 28, 2008, we operated 6,308 retail stores, compared to 6,177 retail stores on June 30, 2007. Total net revenues from new stores accounted for approximately 140 basis points of our total net revenues percentage increase for the thirteen and twenty-six weeks ended June 28, 2008 and June 30, 2007.



Total net revenues continued to benefit from our active relocation program, which moves existing in-line shopping center stores to larger, more convenient, freestanding locations. Historically, we have achieved significant improvements in customer count and net revenue when we do this. As such, our relocation strategy remains an important component of our overall growth strategy. As of June 28, 2008, approximately 65% of our existing stores were freestanding, compared to approximately 63% at June 30, 2007.

---

**Table of Contents**

**Part I**

**Item 2**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

During the thirteen and twenty-six weeks ended June 30, 2007, total net revenues were significantly affected by the acquisition of the Standalone Drug Business on June 2, 2006.

Pharmacy revenue growth continued to benefit from new market expansions, increased penetration in existing markets, the introduction of a prescription drug benefit under Medicare Part D in 2006, our ability to attract and retain managed care customers and favorable industry trends. These trends include an aging American population; many baby boomers are now in their fifties and sixties and are consuming a greater number of prescription drugs. In addition, the increased use of pharmaceuticals as the first line of defense for individual healthcare also contributed to the growing demand for pharmacy services. We believe these favorable industry trends will continue.

Pharmacy revenue dollars continue to be negatively impacted in both periods by the conversion of brand named drugs to equivalent generic drugs, which typically have a lower selling price. In addition, our pharmacy growth has also been adversely affected by a decline in the number of significant new brand named drug introductions, higher consumer co-payments and co-insurance arrangements, by an increase in the number of over-the-counter remedies that were historically only available by prescription and by the growth of the mail order channel. We may choose not to participate in certain prescription benefit programs that fall below our minimum profitability standards. In the event we elect to, for any reason, withdraw from current programs and/or decide not to participate in future programs, we may not be able to sustain our current rate of sales growth.

**Gross profit** includes net revenues less the cost of merchandise sold during the reporting period and related purchasing costs, warehousing costs, delivery costs and actual and estimated inventory losses. Retail Pharmacy gross profit as a percentage of net revenues was 29.9% for the thirteen weeks ended June 28, 2008, compared to 29.3% of net revenues for the comparable 2007 period. Retail Pharmacy gross profit for the twenty-six weeks ended June 28, 2008 was 29.8% of net revenues, compared to 28.5% of net revenues in the comparable 2007 period.

As you review our Retail Pharmacy Segment's performance in this area, we believe you should consider the following important information:

Our pharmacy gross profit rate continued to benefit from an increase in the sale of generic drugs, which normally yield a higher gross profit rate than equivalent brand name drug revenues. However, the increased use of generic drugs increased the pressure from third party payors to reduce reimbursement payments to retail pharmacies for generic drugs, which reduced the benefit we realized from brand to generic product conversions. We expect this trend to continue.

Our pharmacy gross profit rate benefited from a portion of the significant purchasing synergies resulting from the Caremark Merger. We expect the benefit from purchasing synergies to positively impact our pharmacy gross profit rate through fiscal 2008, as we realize a full year benefit from the Caremark Merger.

Sales to customers covered by third party insurance programs have continued to increase and, thus, have become a larger component of our retail pharmacy business. On average, our gross profit on third party pharmacy revenues is lower than our gross profit on cash pharmacy revenues. Third party revenues were 95.8% of total pharmacy revenues during the thirteen and twenty-six weeks ended June 28, 2008, compared to 95.0% and 95.1% of total pharmacy revenues, respectively, during the comparable 2007 periods. We expect this trend to continue.

---

**Table of Contents****Part I****Item 2****Management's Discussion and Analysis of Financial Condition and Results of Operations**

In February 2006, the President signed into law the Deficit Reduction Act of 2005 (the "DRA"), which sought to reduce federal spending by altering the Medicaid reimbursement formula for multi-source (i.e., generic) drugs. These changes were scheduled to begin to take effect during the first quarter of 2007 and were expected to result in reduced Medicaid reimbursement rates for retail pharmacies. According to the Congressional Budget Office, retail pharmacies were expected to negotiate with individual states for higher dispensing fees to mitigate the adverse effect of these changes. During 2007, the Centers for Medicare and Medicaid Services ("CMS") issued a final rule purporting to implement the new reimbursement formula. In December 2007, the U.S. District Court for the District of Columbia preliminarily enjoined CMS from implementing the new rule to the extent such action affects Medicaid reimbursement rates for retail pharmacies. In addition, in July 2008, the Medicare Improvements for Patients and Providers Act of 2008 (the "MIPPA") became law. Among other things, the MIPPA delayed implementation of the new Medicaid reimbursement formula until September 30, 2009 at the earliest. Accordingly, the timing and extent of any reductions and the impact on the Company cannot be determined at this time.

Our pharmacy gross profit rates have been adversely affected by the efforts of managed care organizations, pharmacy benefit managers, governmental and other third party payors to reduce their prescription costs. In the event this trend continues, we may not be able to sustain our current rate of revenue growth and gross profit dollars could be adversely impacted.

Our front store revenues decreased as a percentage of total revenues during the thirteen weeks ended June 28, 2008. On average our gross profit on front store revenues is higher than our gross profit on pharmacy revenues. Pharmacy revenues as a percentage of total revenues for the thirteen and twenty-six weeks ended June 28, 2008 were 67.8% and 68.0%, respectively, compared to 67.6% and 68.1% in the comparable 2007 periods, respectively.

Front store gross profit rate benefited from improved product mix and benefits from our ExtraCare loyalty program.

**Operating expenses**, which include store and administrative payroll, employee benefits, store and administrative occupancy costs, selling expenses, advertising expenses, administrative expenses and depreciation and amortization expense, decreased to 22.6% of total net revenues during the thirteen weeks ended June 28, 2008, compared to 22.8% of net revenues during the comparable 2007 period. Operating expenses for the twenty-six weeks ended June 28, 2008 and the comparable 2007 period were 22.5% of total net revenues. Total operating expenses as a percentage of net revenues decreased during the thirteen weeks ended June 28, 2008 as a result of decreased payroll and benefit costs. Total operating expenses as a percentage of net revenues increased during the twenty-six weeks ended June 28, 2008, as a result of declining revenue leverage. The declining revenue leverage is due in part to continued pressure from the sale of generic drugs, which typically have a lower selling price than their brand named equivalents' selling price and from MinuteClinic operations, which operate at a higher operating expense ratio than the CVS/pharmacy stores.

**Table of Contents****Part I****Item 2****Management's Discussion and Analysis of Financial Condition and Results of Operations****Pharmacy Services Segment**

The following table summarizes our Pharmacy Services Segment's performance for the respective periods:

(In millions)	<i>13 Weeks Ended</i>		<i>26 Weeks Ended</i>	
	<b>June 28, 2008</b>	June 30, 2007	<b>June 28, 2008</b>	June 30, 2007
<b>As reported:</b>				
Net revenues <sup>(1)</sup>	<b>\$ 10,656.8</b>	\$ 10,554.1	<b>\$ 21,421.5</b>	\$ 12,664.4
Gross profit	<b>849.9</b>	862.8	<b>1,637.9</b>	1,060.3
Gross profit % of net revenues	<b>8.0%</b>	8.2%	<b>7.6%</b>	8.4%
Operating expenses	<b>235.8</b>	280.8	<b>493.8</b>	367.7
Operating expense % of net revenues	<b>2.2%</b>	2.7%	<b>2.3%</b>	2.9%
Operating profit	<b>614.1</b>	582.0	<b>1,144.1</b>	692.6
Operating profit % of net revenues	<b>5.8%</b>	5.5%	<b>5.3%</b>	5.5%
Net revenues:				
Mail service	<b>\$ 3,620.8</b>	\$ 4,171.7	<b>\$ 7,267.9</b>	\$ 5,381.4
Retail network	<b>6,942.9</b>	6,296.5	<b>13,966.7</b>	7,182.4
Other	<b>93.1</b>	85.9	<b>186.9</b>	100.6
<b>Comparable Financial Information: <sup>(2)</sup></b>				
Net revenues	<b>\$ 10,656.8</b>	\$ 10,554.1	<b>\$ 21,421.5</b>	\$ 21,075.0
Gross profit	<b>849.9</b>	862.8	<b>1,637.9</b>	1,620.8
Gross profit % of net revenues	<b>8.0%</b>	8.2%	<b>7.6%</b>	7.7%
Operating expenses	<b>235.8</b>	265.2	<b>493.8</b>	732.3
Merger and integration costs <sup>(3)</sup>	<b>(5.0)</b>	(18.8)	<b>(15.4)</b>	(234.0)
Total operating expenses	<b>230.8</b>	246.4	<b>478.4</b>	498.3
Operating expense % of net revenues	<b>2.2%</b>	2.3%	<b>2.2%</b>	2.4%
Operating profit	<b>619.1</b>	616.4	<b>1,159.5</b>	1,122.5
Operating profit % of net revenues	<b>5.8%</b>	5.8%	<b>5.4%</b>	5.3%
Net revenues:				
Mail service	<b>\$ 3,620.8</b>	\$ 4,171.7	<b>\$ 7,267.9</b>	\$ 8,336.6
Retail network	<b>6,942.9</b>	6,296.5	<b>13,966.7</b>	12,570.0
Other	<b>93.1</b>	85.9	<b>186.9</b>	168.4
Pharmacy claims processed:				
Total	<b>151.3</b>	151.2	<b>308.1</b>	303.6
Mail service	<b>15.0</b>	18.5	<b>30.3</b>	37.0
Retail network	<b>136.3</b>	132.7	<b>277.8</b>	266.6
Generic dispensing rate:				
Total	<b>64.5%</b>	59.6%	<b>64.3%</b>	59.2%
Mail service	<b>54.5%</b>	47.6%	<b>53.6%</b>	46.7%
Retail network	<b>65.5%</b>	61.2%	<b>65.3%</b>	60.7%
Mail order penetration rate	<b>23.5%</b>	28.2%	<b>23.3%</b>	28.2%

- (1) Effective September 1, 2007, we converted a number of the PharmaCare retail pharmacy network contracts to the Caremark contract structure, which resulted in those contracts being accounted for using the gross method. This change caused total net revenues to increase by approximately \$667.6 million and \$1.4 billion during the thirteen weeks and twenty-six weeks ended June 28, 2008, respectively.



**Table of Contents****Part I****Item 2****Management's Discussion and Analysis of Financial Condition and Results of Operations**

- (2) The Comparable Financial Information combines the historical Pharmacy Services Segment results of CVS and Caremark assuming the Caremark Merger and any adjustments to the estimated assets acquired and liabilities assumed as of March 22, 2007 occurred at the beginning of the twenty-six week period ended June 30, 2007. Accordingly, the comparable results include incremental depreciation and amortization resulting from the fixed and intangible assets recorded in connection with the Caremark Merger and exclude merger-related expenses and integration costs. **The comparable financial information, which is used by management to assess year-to-year performance, has been provided for illustrative purposes only and does not purport to be indicative of the actual results that would have been achieved by the combined business segment for the periods presented or that will be achieved by the combined business segment in the future.**
- (3) Merger and integration costs for the thirteen and twenty-six weeks ended June 28, 2008 primarily consist of system integration and facility consolidation costs. Merger and integration costs for the thirteen weeks ended June 30, 2007 include \$10.6 million of severance and retention costs and \$8.2 million of other merger-related costs. Merger and integration costs for the twenty-six weeks ended June 28, 2008 primarily consist of severance and retention, system integration and facility consolidation costs. Merger and integration costs for the twenty-six weeks ended June 30, 2007, include \$80.3 million of stock option expense associated with the accelerated vesting of certain Caremark stock options, which vested upon consummation of the merger due to change in control provisions of the underlying Caremark stock option plans, \$42.9 million of change in control payments due upon the consummation of the merger due to change in control provisions in certain Caremark employment agreements and merger-related costs of \$110.9 million. Merger-related costs include \$43.8 million of investment banker fees, \$32.8 million of legal and accounting fees and \$34.3 million of other merger-related costs.

**Net revenues** ~ As you review our Pharmacy Services Segment's revenue performance, we believe you should consider the following important information:

The Caremark Merger significantly affected net revenues during the twenty-six weeks ended June 28, 2008. The inclusion of 182 days of Caremark's operations during the twenty-six weeks ended June 28, 2008, compared to only 101 days during the twenty-six weeks ended June 30, 2007 caused net revenues to increase approximately \$7.9 billion during 2008.

The Pharmacy Services Segment recognizes revenues for its national retail pharmacy network transactions based on individual contract terms. In accordance with Emerging Issues Task Force Issue No. 99-19, Reporting Revenue Gross as a Principal versus Net as an Agent, (EITF 99-19), Caremark's contracts are predominantly accounted for using the gross method whereas, prior to September 2007, PharmaCare's contracts were accounted for using the net method. Effective September 1, 2007, we converted a number of the PharmaCare retail pharmacy network contracts to the Caremark contract structure, which resulted in those contracts being accounted for using the gross method. As a result, net revenues increased by approximately \$667.6 million and \$1.4 billion during the thirteen and twenty-six weeks ended June 28, 2008, respectively.

Changes in mail service and retail network revenue are primarily impacted by changes in pharmacy claims processed, drug cost inflation, customer and claims mix, customer pricing and generic dispensing rates. Increases in generic dispensing rates have the effect of reducing total net revenues. Our business model is built around the alignment of our financial interests with those of our customers and their participants by making the use of prescription drugs safer and more affordable. Our clients and their participants benefit from the lower cost of generic drugs. Our net revenues are reduced as generic dispensing rates increase, however, our gross profit and gross profit margins generally increase with the corresponding increase in generic dispensing rates since generic drug revenues normally yield a higher gross profit rate than equivalent brand name drug revenues.

---

**Table of Contents****Part I****Item 2****Management's Discussion and Analysis of Financial Condition and Results of Operations**

During the thirteen and twenty-six weeks ended June 28, 2008, mail service claims processed decreased to 15.0 million and 30.3 million claims, respectively, or 18.9% and 18.1%, compared to 18.5 million and 37.0 million claims in the thirteen and twenty-six weeks ended June 30, 2007, respectively, on a comparable basis. Mail service claims decreased primarily due to the termination of the Federal Employees Health Benefit Plan ( FEP ) mail contract on December 31, 2007. Our average revenue per mail service claim increased by 7.0% and 6.7% during the thirteen and twenty-six weeks ended June 28, 2008, respectively. Average revenue per mail service claim was impacted primarily by claims mix, generic dispensing rates and drug inflation. Specialty mail service claims, which have significantly higher average net revenues per claim, increased our average mail service revenue per claim by 9.2% and 8.8% during the thirteen and twenty-six weeks ended June 28, 2008, respectively. This increase was primarily attributable to an increase in the percentage of total mail service claims represented by specialty mail service claims and drug cost inflation.

Our average revenue per mail service claim, excluding specialty mail service claims, decreased 2.2% and 2.1% during the thirteen and twenty-six weeks ended June 28, 2008, respectively. This decrease was primarily attributable to an increase in the percentage of generic drugs dispensed. Mail service generic dispensing rates increased to 54.5% and 53.6% for the thirteen and twenty-six weeks ended June 28, 2008, respectively, compared to 47.6% and 46.7% for the thirteen and twenty-six weeks ended June 30, 2007, respectively, on a comparable basis. The 690 basis point increase in generic dispensing rate was primarily attributable to new generic drug introductions during 2007 and the thirteen and twenty-six weeks ended June 28, 2008, as well as our continued efforts to encourage plan participants to utilize generic drugs when available. In addition, the termination of the FEP mail contract resulted in a 100 basis point increase in the mail service generic dispensing rate.

During the thirteen and twenty-six weeks ended June 28, 2008, retail network claims processed increased to 136.3 million and 277.8 million claims, respectively, compared to 132.7 million and 266.6 million for the thirteen and twenty-six weeks ended June 30, 2007, respectively, on a comparable basis. Retail network claims processed increased primarily due to increased enrollment in our Medicare Part D business. Average revenue per retail network claim processed increased by 7.4% and 6.6% during the thirteen and twenty-six weeks ended June 28, 2008, respectively. The change in revenue recognition for PharmaCare contracts previously discussed increased our average revenue per retail network claim processed by approximately 10.3% and 10.5% during the thirteen and twenty-six weeks ended June 28, 2008, respectively. In addition, our average revenue per retail network claim processed decreased approximately 2.9% and 3.9% during the thirteen and twenty-six weeks ended June 28, 2008, respectively, primarily due to customer and claims mix and an increase in the percentage of generic drugs dispensed offset by drug cost inflation. Our retail network generic dispensing rates increased to 65.5% and 65.3% for the thirteen and twenty-six weeks ended June 28, 2008, respectively, compared to 61.2% and 60.7% for the thirteen and twenty-six weeks ended June 30, 2007, respectively, on a comparable basis. The 430 and 460 basis point increase in generic dispensing rate was comparable to that in our mail service claims excluding the effect of the FEP mail contract and is attributable to the same industry dynamics. We anticipate that our generic dispensing rates will increase in future periods; however, the magnitude of the increases will be determined by new generic drug introductions and our efforts to encourage plan participants to utilize generic drugs when available.

**Gross profit** includes net revenues less cost of revenues. Cost of revenues includes the cost of pharmaceuticals dispensed, either directly through our mail service and specialty retail pharmacies or indirectly through our national retail pharmacy network, shipping and handling costs and the operating costs of our mail service pharmacies, customer service operations and related information technology support. Gross profit as a percentage of revenues was 8.0% and 7.6% for the thirteen and twenty-six weeks ended June 28, 2008, respectively, compared to 8.2% and 8.4% for the thirteen and twenty-six weeks ended June 30, 2007, respectively.

---

**Table of Contents**

**Part I**

**Item 2**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

During the twenty-six weeks ended June 28, 2008, the Caremark Merger significantly affected our gross profit. As you review our Pharmacy Services Segment's performance in this area, we believe you should consider the following important information:

As discussed above, our national retail network contracts are reviewed on an individual basis to determine if the revenues should be accounted for using the gross or net method under applicable accounting rules. Under these rules the majority of Caremark's national retail network contracts are accounted for using the gross method, resulting in increased revenues, increased cost of revenues and lower gross profit rates. Accordingly, the conversion of PharmaCare contracts to the Caremark contract structure, effective September 2007, also resulted in increased revenues, increased cost of revenues and lower gross profit margins. During the thirteen and twenty-six weeks ended June 28, 2008, our gross profit rate was negatively impacted by the recording of PharmaCare contracts on a gross basis. The recording of these revenues on a gross basis did not impact the actual gross profit amount; however, it did decrease the gross profit percentage by approximately 50 basis points.

During the twenty-six weeks ended June 28, 2008 and June 30, 2007, our gross profit as a percentage of total net revenues was 7.6% and 7.7%, respectively, on a comparable basis. During the thirteen and twenty-six weeks ended June 30, 2008, our gross profit rate benefited from a portion of the significant purchasing synergies resulting from the Caremark Merger. We expect the benefit from purchasing synergies to continue to positively impact our pharmacy gross profit rate through the remainder of fiscal 2008. In addition, our gross profit rate was negatively impacted by the recording of PharmaCare contracts on a gross basis as discussed above.

Our gross profit rate benefited from an increase in our generic dispensing rates. Total generic dispensing rates increased to 64.5% and 64.3% for the thirteen and twenty-six weeks ended June 28, 2008, respectively, compared to 59.6% and 59.2% for the thirteen and twenty-six weeks ended June 30, 2007, respectively, on a comparable basis. As previously discussed, our net revenues are reduced as generic dispensing rates increase, however, our gross profit and gross profit margins generally increase with the corresponding increase in generic dispensing rates. However, the increased use of generic drugs is increasing the pressure from clients to reduce pharmacy reimbursement payments for generic drugs. We anticipate that our generic dispensing rates will increase in future periods which benefits our customers, plan participants and our financial performance. However, our gross profits are continually impacted by our ability to profitably retain our existing customers and win new business, and maintain and enhance our drug purchase discounts from manufacturers, wholesalers and retail pharmacies.

**Total operating expenses**, which include selling, general and administrative expenses (including integration and other related expenses), amortization related to selling, general and administrative activities and retail specialty pharmacy store and administrative payroll, employee benefits and occupancy costs decreased to 2.2% and 2.3% of net revenues during the thirteen and twenty-six weeks ended June 28, 2008, respectively, compared to 2.7% and 2.9% during the thirteen and twenty-six weeks ended June 30, 2007, respectively.



**Table of Contents**

**Part I**

**Item 2**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

As you review our Pharmacy Services Segment's performance in this area, we believe you should consider the following important information:

During the thirteen weeks ended June 28, 2008, total operating expenses decreased 16.0% to \$235.8 million compared to \$280.8 million during the thirteen weeks ended June 30, 2007. Total operating expenses for the thirteen weeks ended June 28, 2008 include \$5.0 million of integration and other related expenses compared to \$18.8 million for the thirteen weeks ended June 30, 2007. In addition, total operating expenses for the thirteen weeks ended June 28, 2008 include \$52.3 million of amortization expense resulting from the intangible assets recorded in connection with the Caremark Merger compared to \$67.1 million of amortization expense resulting from the preliminary intangible assets recorded in connection with the Caremark Merger in the thirteen weeks ended June 30, 2007. Please see Note 2 to the consolidated condensed financial statements for additional information regarding the Caremark Merger.

On a comparable basis, during the thirteen weeks ended June 28, 2008, total operating expenses decreased 6.3% to \$230.8 million, or 2.2% of net revenue, compared to \$246.4 million, or 2.3% of net revenue, during the thirteen weeks ended June 30, 2007. Comparable results include incremental amortization resulting from the intangible assets recorded in connection with the Caremark Merger and exclude merger-related expenses and integration costs.

During the twenty-six weeks ended June 28, 2008, the Caremark Merger significantly affected our operating expenses. Total operating expenses for the twenty-six weeks ended June 28, 2008 include \$15.4 million of integration and other related expenses and \$34.8 million of incremental amortization expense resulting from the intangible assets recorded in connection with the Caremark Merger. During the twenty-six weeks ended June 28, 2008, total operating expenses decreased 4.0% to \$478.4 million, or 2.2% of net revenue, compared to \$498.3 million, or 2.4% of net revenue, during the twenty-six weeks ended June 30, 2007, on a comparable basis.

**Table of Contents****Part I****Item 2****Management's Discussion and Analysis of Financial Condition and Results of Operations****Liquidity and Capital Resources**

We anticipate that cash flows from operations, supplemented by short-term commercial paper and long-term borrowings, will continue to fund the future growth of our business.

*Net cash provided by operating activities* decreased to \$1,392.1 million during the twenty-six weeks ended June 28, 2008, compared to \$1,427.2 million during the comparable 2007 period. The decrease in net cash provided by operations during the twenty-six weeks ended June 28, 2008 primarily resulted from increased interest paid as a result of higher average debt balances and increased taxes paid resulting from increased income.

*Net cash used in investing activities* decreased to \$0.9 billion during the twenty-six weeks ended June 28, 2008, compared to \$2.7 billion during the comparable 2007 period. The decrease in net cash used in investing activities was due to less acquisition activity during 2008 as 2007 included the Caremark Merger. Gross capital expenditures totaled \$955.3 million for the twenty-six weeks ended June 28, 2008, compared to \$778.0 million in the comparable 2007 period. The majority of the cash used for capital expenditures in both reporting periods supported the Retail Pharmacy Segment's real estate development program.

During the twenty-six weeks ended June 28, 2008, we opened 90 new retail pharmacy stores and closed 27 retail pharmacy stores, 2 mail order pharmacies and 1 specialty mail order pharmacy. In addition, the Company relocated 92 retail pharmacy stores and 1 specialty pharmacy store. For the remainder of 2008, we plan to open 120-130 new or relocated retail pharmacy stores.

*Net cash used in financing activities* was \$1.0 billion during the twenty-six weeks ended June 28, 2008, compared to net cash provided by financing activities of \$1.6 billion during the comparable 2007 period. Net cash used in financing activities was related to the payment of commercial paper and the repurchase of common stock during the twenty-six weeks ended June 28, 2008. Net cash provided by financing activities during the twenty-six weeks ended June 30, 2007, was primarily due to increased long-term borrowings to fund the Caremark Merger offset, in part, by the repayment of short-term borrowings and the repurchase of common shares through the tender offer and accelerated share repurchase program. In July 2008, our Board of Directors authorized a 15% increase in our quarterly common stock dividend to \$0.069 per share on the Company's common stock payable August 1, 2008 to holders of record on July 21, 2008. This increase equates to an annual dividend rate of \$0.276 per share.

We had \$980.0 million of commercial paper outstanding at a weighted average interest rate of 2.8% as of June 28, 2008. In connection with our commercial paper program, we maintain a \$675 million, five-year unsecured back-up credit facility, which expires on June 11, 2009, a \$675 million, five-year unsecured back-up credit facility, which expires on June 2, 2010, a \$1.4 billion, five-year unsecured back-up credit facility, which expires on May 12, 2011 and a \$1.3 billion, five-year unsecured back-up credit facility, which expires on March 12, 2012. The credit facilities allow for borrowings at various rates that are dependent in part on our public debt rating. As of June 28, 2008, we had no outstanding borrowings against the credit facilities.

On May 9, 2007, our Board of Directors authorized a share repurchase program for up to \$5.0 billion of our outstanding common stock. The share repurchase program was completed during 2007 through a \$2.5 billion fixed dollar accelerated share repurchase agreement (the "May ASR agreement"), under which final settlement occurred in October 2007 and resulted in the repurchase of 67.5 million shares of common stock; an open market repurchase program, which concluded in November 2007 and resulted in 5.3 million shares of common stock being repurchased for \$211.9 million; and a \$2.3 billion fixed accelerated share repurchase agreement (the "November ASR agreement"), which resulted in an initial 51.6 million shares of common stock being purchased and placed into our treasury account as of December 29, 2007. The final settlement under the November ASR agreement occurred on March 28, 2008 and resulted in us receiving an additional 5.7 million shares of common stock, which were placed into our treasury account as of March 29, 2008.

---

**Table of Contents**

**Part I**

**Item 2**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

On May 7, 2008, our Board of Directors authorized, effective May 21, 2008, a share repurchase program for up to \$2.0 billion of outstanding common stock. The specific timing and amount of repurchases will vary based on market conditions and other factors. During the second quarter ended June 28, 2008, we repurchased 0.6 million shares of common stock for \$23.0 million. The shares were placed into our treasury account upon delivery. The stock repurchase program may be modified, extended or terminated by our Board of Directors at any time. We will continue to evaluate alternatives for optimizing our capital structure on an ongoing basis.

Our credit facilities, unsecured senior notes and Enhanced Capital Advantaged Preferred Securities contain customary restrictive financial and operating covenants. These covenants do not include a requirement for the acceleration of our debt maturities in the event of a downgrade in our credit rating. We do not believe the restrictions contained in these covenants materially affect our financial or operating flexibility.

As of June 28, 2008, our long-term debt was rated Baa2 by Moody's and BBB+ by Standard & Poor's, and our commercial paper program was rated P-2 by Moody's and A-2 by Standard & Poor's. Upon completion of the Caremark Merger in March 2007, Standard & Poor's raised the Company's credit watch outlook from negative to stable. On May 15, 2008, Moody's raised the Company's credit watch from stable to positive. In assessing our credit strength, we believe that both Moody's and Standard & Poor's considered, among other things, our capital structure and financial policies as well as our consolidated balance sheet, the Caremark Merger and other financial information. Although we currently believe our long-term debt ratings will remain investment grade, we cannot guarantee the future actions of Moody's and/or Standard & Poor's. Our debt ratings have a direct impact on our future borrowing costs, access to capital markets and new store operating lease costs.

**Off-Balance Sheet Arrangements**

Between 1991 and 1997, the Company sold or spun off a number of subsidiaries, including Bob's Stores, Linens 'n Things, Marshalls, Kay-Bee Toys, This End Up and Footstar. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the store's lease obligations. When the subsidiaries were disposed of, the Company's guarantees remained in place, although each initial purchaser has indemnified the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries were to become insolvent and failed to make the required payments under a store lease, the Company could be required to satisfy these obligations. As of December 29, 2007, the Company guaranteed approximately 220 such store leases, with the maximum remaining lease term extending through 2022. Assuming that each respective purchaser became insolvent and the Company was required to assume all of these lease obligations, management estimates that the Company could settle the lease obligations for approximately \$325 to \$375 million as of December 29, 2007. Management believes the ultimate disposition of any of the guarantees will not have a material adverse effect on the Company's consolidated financial condition or future cash flows. Please see "Loss from discontinued operations" discussed above for further information regarding our guarantee of Linens 'n Things' store lease obligations.

---

**Table of Contents****Part I****Item 2****Management's Discussion and Analysis of Financial Condition and Results of Operations****Critical Accounting Policies**

We prepare our consolidated financial statements in conformity with generally accepted accounting principles, which requires management to make certain estimates and apply judgments. We base our estimates and judgments on historical experience, current trends and other factors that management believes to be important at the time the consolidated condensed financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our consolidated condensed financial statements.

While we believe that the historical experience, current trends and other factors considered support the preparation of our consolidated condensed financial statements in conformity with generally accepted accounting principles, actual results could differ from our estimates and such differences could be material. Please read our 2007 Form 10-K for a complete discussion of all of our significant accounting policies. We believe the following accounting policies include a higher degree of judgment and/or complexity and, thus, are considered to be critical accounting policies. The critical accounting policies discussed below are applicable to both of our business segments. We have discussed the development and selection of our critical accounting policies with the Audit Committee of our Board of Directors and the Audit Committee has reviewed our disclosures relating to them.

**Goodwill and Intangible Assets**

We account for goodwill and intangible assets in accordance with SFAS No. 141, Business Combinations, SFAS No. 142, Goodwill and Other Intangible Assets and SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets.

Identifiable intangible assets consist primarily of trademarks, customer contracts and relationships, favorable and unfavorable leases and covenants not to compete. These intangible assets arise primarily from the allocation of the purchase price of businesses acquired to identifiable intangible assets based on their respective fair market values at the date of acquisition. Amounts assigned to identifiable intangible assets, and their related useful lives, are derived from established valuation techniques and management estimates. Goodwill represents the excess of amounts paid for acquisitions over the fair market value of the net identifiable assets acquired.

We evaluate the recoverability of certain long-lived assets, including intangible assets with finite lives, but excluding goodwill and intangible assets with indefinite lives, which are tested for impairment using separate tests, whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We group and evaluate these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. When evaluating these long-lived assets for potential impairment, we first compare the carrying amount of the asset group to the asset group's estimated future cash flows (undiscounted and without interest charges). If the estimated future cash flows are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group's estimated future cash flows (discounted and with interest charges). If required, an impairment loss is recorded for the portion of the asset group's carrying value that exceeds the asset group's estimated future cash flows (discounted and with interest charges).

Our long-lived asset impairment loss calculation contains uncertainty since we must use judgment to estimate each asset group's future sales, profitability and cash flows. When preparing these estimates, we consider historical results and current operating trends and our consolidated sales, profitability and cash flow results and forecasts. These estimates can be affected by a number of factors including, but not limited to, general economic conditions, efforts of third party organizations to reduce their prescription drug costs and/or increased member co-payments, the continued efforts of competitors to gain market share and consumer spending patterns.

Goodwill and indefinitely-lived intangible assets are subject to impairment reviews annually, or if changes or events indicate the carrying value may not be recoverable. Indefinitely-lived intangible assets are tested by comparing the estimated fair value of the asset to its carrying value. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized and the asset is written down to its estimated fair value.

---

**Table of Contents**

**Part I**

**Item 2**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

Our indefinitely-lived intangible asset impairment loss calculation contains uncertainty since we must use judgment to estimate the fair value based on the assumption that in lieu of ownership of an intangible asset, the Company would be willing to pay a royalty in order to utilize the benefits of the asset. Value is estimated by discounting the hypothetical royalty payments to their present value over the estimated economic life of the asset. These estimates can be affected by a number of factors including, but not limited to, general economic conditions, availability of market information as well as the profitability of the Company.

Goodwill is tested on a reporting unit basis using the expected present value of future cash flows. In accordance with SFAS 142, goodwill impairment is determined using a two-step process. The first step of the impairment test is to identify potential impairment by comparing the reporting unit's fair value with its net book value (or carrying amount), including goodwill. If the fair value of the reporting unit exceeds its carrying amount, the reporting unit's goodwill is not considered to be impaired and the second step of the impairment test is not performed.

If the carrying amount of the reporting unit's carrying amount exceeds its fair value, the second step of the impairment test is performed to measure the amount of impairment loss, if any. The second step of the impairment test compares the implied fair value of the reporting unit's goodwill with the carrying amount of the goodwill. If the carrying amount of the reporting unit's goodwill exceeds the implied fair value of the goodwill, an impairment loss is recognized in an amount equal to that excess.

Our impairment loss calculation contains uncertainty since we must use judgment to estimate each reporting unit's future revenues, profitability and cash flows. When preparing these estimates, we consider each reporting unit's historical results and current operating trends and our consolidated revenues, profitability and cash flow results and forecasts. These estimates can be affected by a number of factors including, but not limited to, general economic conditions, efforts of third party organizations to reduce their prescription drug costs and/or increase member co-payments, the continued efforts of competitors to gain market share and consumer spending patterns.

The carrying value of goodwill and intangible assets covered by this critical accounting policy was \$34.2 billion as of June 28, 2008. We did not record any impairment losses related to goodwill or intangible assets during 2008, 2007 or 2006. Although we believe we have sufficient current and historical information available to us to test for impairment, it is possible that actual cash flows could differ from the estimated cash flows used in our impairment tests. Due to the nature of the uncertainties discussed above, we cannot determine a reasonably likely change.

We have not made any material changes in the methodologies utilized to test the carrying values of goodwill and intangible assets for impairment during the past three years.

**Closed Store Lease Liability**

We account for closed store lease termination costs in accordance with SFAS No. 146, *Accounting for Costs Associated with Exit or Disposal Activities*, subsequent to its adoption in 2003. As such, when a leased store is closed, we record a liability for the estimated present value of the remaining obligation under the non-cancelable lease, which includes future real estate taxes, common area maintenance and other charges, if applicable. The liability is reduced by estimated future sublease income.

The initial calculation and subsequent evaluations of our closed store lease liability contain uncertainty since we must use judgment to estimate the timing and duration of future vacancy periods, the amount and timing of future lump sum settlement payments and the amount and timing of potential future sublease income. When estimating these potential termination costs and their related timing, we consider a number of factors, which include, but are not limited to, historical settlement experience, the owner of the property, the location and condition of the property, the terms of the underlying lease, the specific marketplace demand and general economic conditions.

---

**Table of Contents**

**Part I**

**Item 2**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

Our total closed store lease liability covered by this critical accounting policy was \$486.1 million as of June 28, 2008. This amount is net of \$341.0 million of estimated sublease income that is subject to the uncertainties discussed above. Although we believe we have sufficient current and historical information available to us to record reasonable estimates for sublease income, it is possible that actual results could differ. In order to help you assess the risk, if any, associated with the uncertainties discussed above, a ten percent (10%) pre-tax change in our estimated sublease income, which we believe is a reasonably likely change, would increase or decrease our total closed store lease liability by about \$34.1 million as of June 28, 2008.

We have not made any material changes in the reserve methodology used to record closed store lease reserves during the past three years.

**Self-Insurance Liabilities**

We are self-insured for certain losses related to general liability, workers' compensation and auto liability, although we maintain stop loss coverage with third party insurers to limit our total liability exposure. We are also self-insured for certain losses related to health and medical liabilities.

The estimate of our self-insurance liability contains uncertainty since we must use judgment to estimate the ultimate cost that will be incurred to settle reported claims and unreported claims for incidents incurred but not reported as of the balance sheet date. When estimating our self-insurance liability, we consider a number of factors, which include, but are not limited to, historical claim experience, demographic factors and severity factors. On a quarterly basis, we review our assumptions to determine if our self-insurance liability is adequate as it relates to our general liability, workers' compensation and auto liability. Similar reviews are conducted semi-annually to determine that our self insurance liability is adequate for our health and medical liability.

Our total self-insurance liability covered by this critical accounting policy was \$354.1 million as of June 28, 2008. Although we believe we have sufficient current and historical information available to us to record reasonable estimates for our self-insurance liability, it is possible that actual results could differ. In order to help you assess the risk, if any, associated with the uncertainties discussed above, a ten percent (10%) pre-tax change in our estimate for our self-insurance liability, which we believe is a reasonably likely change, would increase or decrease our self-insurance liability by about \$35.4 million as of June 28, 2008.

We have not made any material changes in the accounting methodology used to establish our self-insurance liability during the past three years.

**Inventory**

Our inventory is stated at the lower of cost or market on a first-in, first-out basis using the retail method of accounting to determine cost of sales and inventory in our stores, average cost to determine cost of sales and inventory in our mail service and specialty pharmacies and the cost method of accounting to determine inventory in our distribution centers. Under the retail method, inventory is stated at cost, which is determined by applying a cost-to-retail ratio to the ending retail value of our inventory. Since the retail value of our inventory is adjusted on a regular basis to reflect current market conditions, our carrying value should approximate the lower of cost or market. In addition, we reduce the value of our ending inventory for estimated inventory losses that have occurred during the interim period between physical inventory counts. Physical inventory counts are taken on a regular basis in each location (other than in nine distribution centers, which perform a continuous cycle count process to validate the inventory balance on hand) to ensure that the amounts reflected in the consolidated financial statements are properly stated.

**Table of Contents**

**Part I**

**Item 2**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

The accounting for inventory contains uncertainty since we must use judgment to estimate the inventory losses that have occurred during the interim period between physical inventory counts. When estimating these losses, we consider a number of factors, which include but are not limited to, historical physical inventory results on a location-by-location basis and current physical inventory loss trends.

Our total reserve for estimated inventory losses covered by this critical accounting policy was \$134.8 million as of June 28, 2008. Although we believe we have sufficient current and historical information available to us to record reasonable estimates for estimated inventory losses, it is possible that actual results could differ. In order to help you assess the aggregate risk, if any, associated with the uncertainties discussed above, a ten percent (10%) pre-tax change in our estimated inventory losses, which we believe is a reasonably likely change, would increase or decrease our total reserve for estimated inventory losses by about \$13.5 million as of June 28, 2008.

We have not made any material changes in the accounting methodology used to establish our inventory loss reserves during the past three years. Although we believe that the estimates discussed above are reasonable and the related calculations conform to generally accepted accounting principles, actual results could differ from our estimates, and such differences could be material.

**Recent Accounting Pronouncements**

In April 2008, the Financial Accounting Standards Board (the FASB) issued a FASB Staff Position (FSP) No. FAS 142-3, Determining the Useful Life of Intangible Assets. FSP No. FAS 142-3 amends the factors an entity should consider in developing renewal or extension assumptions used in determining the useful lives of recognized intangible assets. FSP No. FAS 142-3 is effective for fiscal years beginning after December 15, 2008. We do not believe the adoption of FSP No. FAS 142-3 will have a material impact on our consolidated results of operations, financial position or cash flows.

**Cautionary Statement Concerning Forward-Looking Statements**

The Private Securities Litigation Reform Act of 1995 (the Reform Act) provides a safe harbor for forward-looking statements made by or on behalf of CVS Caremark Corporation. The Company and its representatives may, from time to time, make written or verbal forward-looking statements, including statements contained in the Company's filings with the Securities and Exchange Commission and in its reports to stockholders. Generally, the inclusion of the words believe, expect, intend, estimate, project, anticipate, will, should and similar expressions identify statements that constitute forward-looking statements. All statements addressing operating performance of CVS Caremark Corporation or any subsidiary, events or developments that the Company expects or anticipates will occur in the future, including statements relating to sales growth, earnings or earnings per common share growth, free cash flow, debt ratings, inventory levels, inventory turn and loss rates, store development, relocations and new market entries, as well as statements expressing optimism or pessimism about future operating results or events, are forward-looking statements within the meaning of the Reform Act.

**Table of Contents**

**Part I**

**Item 2**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

The forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons, including but not limited to:

Our ability to realize the incremental revenues, synergies and other benefits from the Caremark Merger as expected, and to successfully integrate the Caremark businesses in accordance with the expected timing;

The continued efforts of health maintenance organizations, managed care organizations, pharmacy benefit management companies and other third party payors to reduce prescription drug costs and pharmacy reimbursement rates, particularly with respect to generic pharmaceuticals;

The possibility of client loss and/or the failure to win new client business;

The frequency and rate of introduction of successful new prescription drugs as well as generic alternatives to existing brand drugs;

The effect on our Pharmacy Services business of a declining margin environment attributable to increased competition in the pharmacy benefit management industry and increased client demands for lower prices, enhanced service offerings and/or higher service levels;

Risks related to our inability to earn and retain purchase discounts and/or rebates from pharmaceutical manufacturers at current levels;

Risks regarding the impact of the Medicare prescription drug benefit on our business;

Risks related to the change in industry pricing benchmarks that could adversely affect our financial performance;

Increased competition from other drugstore chains, supermarkets, discount retailers, membership clubs and Internet companies, as well as changes in consumer preferences or loyalties;

Litigation, legislative and regulatory risks associated with our business or the retail pharmacy business and/or pharmacy benefit management industry generally;

The risks relating to changes in laws and regulations, including changes in accounting standards and taxation requirements (including tax rate changes, new tax laws and revised tax law interpretations);



The risks relating to adverse developments in the healthcare or pharmaceutical industry generally, including, but not limited to, developments in any investigation related to the pharmaceutical industry that may be conducted by any governmental authority;

The strength of the economy in general or the markets we serve, which may impact consumer purchasing power, preferences and/or spending patterns, our ability to attract, hire and retain suitable pharmacists, management, and other employees, our ability to establish effective advertising, marketing and promotional programs, our ability to obtain necessary financing on acceptable terms and our ability to secure suitable store locations under acceptable terms; and

Other risks and uncertainties detailed from time to time in our filings with the Securities and Exchange Commission.

The foregoing list is not exhaustive. There can be no assurance that the Company has correctly identified and appropriately assessed all factors affecting its business. Additional risks and uncertainties not presently known to the Company or that it currently believes to be immaterial also may adversely impact the Company. Should any risks and uncertainties develop into actual events, these developments could have material adverse effects on the Company's business, financial condition and results of operations. For these reasons, you are cautioned not to place undue reliance on the Company's forward-looking statements.

**Table of Contents**

**Part I**

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

As of June 28, 2008, the Company had no derivative financial instruments or derivative commodity instruments in place and believes that its exposure to market risk associated with other financial instruments, principally interest rate risk inherent in its debt portfolio is not material.

**Item 4. Controls and Procedures**

**Evaluation of disclosure controls and procedures:** The Company's Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of June 28, 2008, have concluded that as of such date the Company's disclosure controls and procedures were adequate and effective and designed to ensure that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 that occurred during the second quarter ended June 28, 2008 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

---

**Table of Contents****Part II****Item 1****Legal Proceedings**

1. The Rhode Island Attorney General's Office, the Rhode Island Ethics Commission, and the United States Attorney's Office for the District of Rhode Island have been investigating the business relationships between certain former members of the Rhode Island General Assembly and various Rhode Island companies, including Roger Williams Medical Center, Blue Cross & Blue Shield of Rhode Island and CVS. In connection with the investigation of these business relationships, a former state senator was criminally charged in 2005 by federal and state authorities and has pled guilty to those charges, and a former state representative was criminally charged in October 2007 by federal authorities and has pled guilty to those charges. In January 2007, two CVS employees on administrative leave from the Company were indicted on federal charges relating to their involvement in entering into a \$12,000 per year consulting agreement with the former state senator eight years ago. In May 2008, after a jury trial, both employees were acquitted of all charges. CVS will continue to cooperate fully in this investigation, the timing and outcome of which cannot be predicted with certainty at this time.
  
2. In 2006, a number of shareholder derivative lawsuits were filed in the Tennessee state court and the Tennessee federal court against Caremark and various officers and directors of Caremark seeking, among other things, a declaration that the directors breached their fiduciary duties, imposition of a constructive trust upon any illegal profits received by the defendants and punitive and other damages. The cases brought in the Tennessee federal court were consolidated into one action in August 2006, and the consolidated action was voluntarily dismissed without prejudice by the plaintiffs in March 2007. The cases brought in the Tennessee state court were also consolidated into one action, and the plaintiffs amended their complaint to add CVS and its directors as defendants and to allege class action claims. A stipulation of settlement was entered into by the parties on July 5, 2007, which provided, among other things, that (i) the plaintiffs will dismiss the case and release the defendants from claims asserted in the action, (ii) a temporary restraining order issued by the court in March 2007 will be vacated, (iii) defendants will agree to maintain for at least four years a number of corporate governance provisions relating to the granting, exercise and disclosure of stock option awards and (iv) the defendants will not oppose plaintiffs' petition for an award of attorneys' fees and expenses not to exceed \$7.5 million. As part of the settlement, the defendants specifically denied any liability or wrongdoing with respect to all claims alleged in the litigation, including claims relating to stock option backdating, and acknowledged that they entered into the settlement solely to avoid the distraction, burden and expense of the pending litigation. On July 14, 2008, the settlement was approved by the trial court.
  
3. The Company is also a party to other litigation arising in the normal course of its business, none of which is expected to be material to the Company. The Company can give no assurance, however, that our operating results and financial condition will not be materially adversely affected, or that we will not be required to materially change our business practices, based on: (i) future enactment of new healthcare or other laws or regulations; (ii) the interpretation or application of existing laws or regulations, as they may relate to our business or the pharmacy services industry; (iii) pending or future federal or state governmental investigations of our business or the pharmacy services industry; (iv) institution of government enforcement actions against us; (v) adverse developments in any pending qui tam lawsuit against us, whether sealed or unsealed, or in any future qui tam lawsuit that may be filed against us; or (vi) adverse developments in other pending or future legal proceedings against us or affecting the pharmacy services industry.

**Table of Contents****Part II****Item 2****Unregistered Sales of Equity Securities and Use of Proceeds**

## (c) Stock Repurchases

The following table presents the total number of shares purchased during the second quarter of 2008, the average price paid per share, the number of shares that were purchased as part of a publicly announced tender offer and a separate, subsequent repurchase program, and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the \$2.0 billion repurchase program.

<b>Fiscal Period</b>	<b>Total Number of Shares Purchased</b>	<b>Average Price Paid per Share</b>	<b>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs<sup>(1)</sup></b>	<b>Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs</b>
March 30, 2008 through April 26, 2008				
April 27, 2008 through May 24, 2008				\$ 2,000,000,000
May 25, 2008 through June 28, 2008	550,000	\$ 41.91	550,000	\$ 1,976,949,500

- (1) On May 7, 2008, the Company's Board of Directors authorized, effective May 21, 2008, a share repurchase program for up to \$2.0 billion of outstanding common stock. The specific timing and amount of repurchases will vary based on market conditions and other factors. During the second quarter ended June 28, 2008, the Company repurchased 0.6 million shares of common stock for \$23.0 million. The shares were placed into the Company's treasury account upon delivery. The stock repurchase program may be modified, extended or terminated by the Board of Directors at any time.

**Table of Contents****Part II****Item 4****Submission of Matters to a Vote of Security Holders**

The following matters were submitted to a vote of security holders at our Annual Meeting of Stockholders which was held on Wednesday, May 7, 2008 in Woonsocket, Rhode Island.

	<i>For</i>	<i>Against</i>	<i>Abstained</i>	<i>Broker Non-Votes</i>
1. The election, for one-year terms, of all persons nominated for directors, as set forth in the Company's proxy statement dated March 28, 2008, was approved by the following votes:				
Edwin M. Banks	1,158,184,562	27,930,122		
C. David Brown II	1,169,033,936	17,038,013		
David W. Dorman	1,119,442,248	66,561,487		
Kristen Gibney Williams	1,175,264,010	10,447,406		
Marian L. Heard	1,161,685,298	24,057,160		
William H. Joyce	1,166,721,157	18,732,205		
Jean-Pierre Millon	1,174,663,732	10,981,727		
Terrence Murray	1,164,208,664	21,668,864		
C.A. Lance Piccolo	1,162,275,878	23,474,896		
Sheli Z. Rosenberg	1,138,032,559	44,247,836		
Thomas M. Ryan	1,163,947,494	22,046,412		
Richard J. Swift	1,170,839,460	14,839,386		
	<i>For</i>	<i>Against</i>	<i>Abstained</i>	<i>Broker Non-Votes</i>
2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the 2008 fiscal year, was approved by the following vote:	1,179,436,206	6,638,164	11,707,307	
3. Stockholder proposal regarding special shareholder meetings, as set forth in the Company's proxy statement dated March 28, 2008, was rejected by the following vote:	501,107,111	537,090,591	31,784,340	385,262,158
4. Stockholder proposal regarding tax gross-up payments, as set forth in the Company's proxy statement dated March 28, 2008, was rejected by the following	514,906,805	470,247,984	84,827,254	385,262,157

## Edgar Filing: CVS CAREMARK CORP - Form 10-Q

vote:

5. Stockholder proposal regarding political contributions and expenditures, as set forth in the Company's proxy statement dated March 28, 2008, was rejected by the following vote:

350,471,655 560,985,044 158,525,350 385,262,151

40

**Table of Contents**

**Part II**

**Item 5**

**Other Information**

On July 30, 2008 CVS Caremark and Chris W. Bodine agreed on an amendment to Mr. Bodine's employment agreement to reflect his previously announced transition to retirement in 2010. For the remainder of 2008, Mr. Bodine will continue in his new position as Special Advisor to the CVS Caremark Chief Executive Officer. In 2009, Mr. Bodine will reduce his schedule to a part-time basis until his retirement on his 55th birthday in June 2010. During this period he will work with the Chief Executive Officer on long-term corporate and health care services strategy. Under his amended employment agreement, Mr. Bodine will not receive any equity awards in 2009 or 2010 and his annual and long-term incentive awards will be reduced to reflect his transition to part-time status. In addition, upon his retirement, vesting of outstanding restricted stock units and stock options will occur in accordance with the respective equity award agreements. Mr. Bodine will be subject to non-compete and non-solicitation covenants for 2 years after his retirement.

---

**Table of Contents**

**Part II**

**Item 6**

**Exhibits**

**Item 6. Exhibits**

**Exhibits:**

- 3.1 Amended and Restated Certificate of Incorporation of the Registrant [incorporated by reference to Exhibit 3.1 to Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 1996 (Commission File No. 001-01011)].
- 3.1A Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective May 13, 1998 [incorporated by reference to Exhibit 4.1A to Registrant's Registration Statement No. 333-52055 on Form S-3/A dated May 18, 1998].
- 3.1B Certificate of Amendment to the Amended and Restated Certificate of Incorporation [incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K dated March 22, 2007 (Commission File No. 001-01011)].
- 3.1C Certificate of Merger dated May 9, 2007 [incorporated by reference to Exhibit 3.1C to Registrant's Quarterly Report on Form 10-Q dated November 1, 2007 (Commission File No. 001-01011)].
- 3.2 By-laws of the Registrant, as amended and restated [incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K dated February 5, 2008 (Commission File No. 001-01011)].
- 10.1 Amendment dated as of July 30, 2008 to the Employment Agreement dated as of December 20, 2001 between the Registrant and the Registrant's Executive Vice President and President of CVS Caremark Health Services President.
- 15.1 Letter re: Unaudited Interim Financial Information.
- 31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.
- 32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.

**Signatures:**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.

CVS Caremark Corporation

*(Registrant)*

/s/ David B. Rickard  
David B. Rickard

Executive Vice President,

Chief Financial Officer and



Edgar Filing: CVS CAREMARK CORP - Form 10-Q

Chief Administrative Officer

July 31, 2008